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Abstract 
Atherosclerosis is a chronic inflammatory disease characterized by leukocyte 
infiltration and the deposition of lipids in the arteries. B lymphocytes have 
been found in atherosclerotic lesions but their role in disease development 
remains unclear. In the present study, we found that hypercholesterolemia was 
associated with an expansion of the MZ B cell compartment in atherosclerotic 
apoE-/- mice compared to age-matched WT mice and the induction of disease 
regression through the treatment of atherosclerotic apoE-/- mice with the 
cholesterol lowering drug ezetimibe reversed the expansion of MZ B cells. 
The accumulation of MZ B cells was not due to alterations in their 
development or increased proliferation/activation and BAFF mediated survival. 
Instead, anergic iNKT cells were responsible for the decrease in apoptotic cell 
death in apoE-/- mice as the induction of iNKT cell anergy in WT mice resulted 
in a two fold expansion of MZ B cells. iNKT cell-mediated MZ B cell death 
was dependent on IFN-γ as the reintroduction of functional WT iNKT cells 
but not IFN-γ-/- iNKT cells into apoE-/- mice reversed MZ B cell expansion. 
The expanded MZ B cell compartment may function to internalize lipid 
antigens and secrete lipid specific antibodies such as oxLDL IgM. Taken 
together, these findings support an important role for iNKT cells in the 
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Chapter 1: Introduction 
1.1 Atherosclerosis and Dyslipidemia 
 Atherosclerosis is the underlying condition contributing to cardiovascular 
disease which is the leading cause of morbidity and mortality globally (Murray, 
Vos et al. 2012). This disease is predicted to be the major killer in the next 15 
years which may result in severe consequences on both the individual and society 
at large. Dyslipidemia is the most prevalent and important modifiable risk factor 
for atherosclerosis, affecting one in every two US adults. Dyslipidemia is defined 
as an abnormal plasma lipid status characterized by elevated levels of low density 
lipoprotein (LDL) cholesterol, low levels of high density lipoprotein (HDL) 
cholesterol and an increase in small dense LDL particles (Ballantyne 2007).  
1.2 Atherogenesis 
 Atherosclerosis is a chronic inflammatory disease involving the formation 
of lesions that are characterized by lipid accumulation, infiltration of 
inflammatory cells, followed by cell death and fibrosis in large and medium-sized 
arteries (Hansson and Libby 2006). Atherogenesis refers to the development of 
atheromatous plaques in the inner lining of the arteries, resulting in narrowing of 
the lumen of a blood vessel to the point of obstruction (Breslow 1996, Libby, 
Ridker et al. 2011).  
Lesions tend to form at the branch points of arterial blood vessels and 
progress through three stages. The first stage is the fatty streak lesion, which is 
characterized by the presence of lipid filled macrophages called foam cells in the 
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subendothelial space (Figure 1.1). The second stage is the fibrous plaque 
consisting of a central area containing lipids derived from necrotic foam cells, 
covered by a fibrous cap containing smooth muscle cells and collagen. The final 
stage is the complex lesion which displays thrombus formation with deposition of 
fibrin and platelets (Breslow 1996). (Figure 1.1) 
 
 
Figure 1.1: Schematic diagram of the three stages of atherosclerotic lesion 
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1.3 The Atherosclerotic Process 
 
Figure 1.2 Schematic diagram showing the steps involved in the recruitment 
of mononuclear phagocytes to the atherosclerotic plaque and some of the 
functions of these cells in the mature atheroma. Figure adapted from (Libby 
2002). 
 
The atherosclerotic process is initiated when cholesterol-containing LDL 
accumulate in the arterial intima, undergo oxidative modification to become 
oxidized LDL (oxLDL). OxLDL activates the endothelium (Hansson, Robertson 
et al. 2006), which in turn increased their expression of vascular cell adhesion 
molecule-1 (VCAM-1). This allows circulating monocytes to migrate across the 
endothelium into the arterial intima, a process that is dependent on the interaction 
between monocyte chemoattractant protein-1 (MCP-1) with its receptor CCR2. 
Once monocytes reach the intima, they differentiate into macrophages that uptake 
oxLDL via scavenger receptors to form foam cells, which are characteristic of 
fatty streak lesions. In the arterial intima, foam cells secrete pro-inflammatory 
cytokines which augment the local inflammatory response in the lesion. The 
activated mononuclear phagocytes produce matrix metalloproteinases (MMPs) 
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which degrades the extracellular matrix that strengthens the fibrous cap, resulting 
in plaque rupture. Eventually, the macrophages gather in the central core where 
some die by apoptosis, forming a fibrous plaque (Libby 2002) (Figure 1.2). 
1.4 Murine Models of Atherosclerosis 
Through induced mutations, mice that are susceptible to atherosclerosis 
have been developed to facilitate the study of the disease. Mice deficient for 
apolipoprotein E (apoE-/-) and low density lipoprotein receptor (ldlr-/-) on a 
C57BL/6 background are strains of genetically altered mice that have been 
commonly used in atherosclerotic research (Breslow 1996). ApoE is a surface 
component of lipoproteins which serves as a ligand for lipoprotein receptor 
recognition and clearance from the circulation. ApoE-/- mice have delayed 
clearance of lipoproteins and develop spontaneous hypercholesterolemia, which is 
further exacerbated by a high fat, cholesterol-rich diet (Plump, Smith et al. 1992). 
Elevated plasma cholesterol levels result in the formation of atherosclerotic 
plaques in the arteries at sites which are normally affected in human 
atherosclerosis (Nakashima, Plump et al. 1994, Reddick, Zhang et al. 1994). Ldlr-
/- mice do not develop atherosclerosis spontaneously and needs to be fed on a very 
high cholesterol diet before developing hypercholesterolemia and atherosclerotic 
plaques (Hansson and Libby, 2006). However, there are limitations of studying 
atherosclerosis in mice. Murine models of atherosclerosis will only develop fatty 
streaks and fibrous plaque lesions and are more suitable for studying earlier stages 
of the disease (Whitman 2004). As they do not develop complex atherosclerotic 
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lesions similar to those in humans, histopathological and clinical studies will be 
required to investigate plaque rupture and thrombosis. 	  
1.5 The Immune System and Atherosclerosis 
A growing body of evidence supports the role of inflammation and 
immunity in the pathogenesis of atherosclerosis. Studies in cardiovascular 
diseases have suggested both pro- and anti-atherogenic roles for immunity. Like 
monocytes and macrophages, many other immune cells such as T cells, natural 
killer cells (NK), NKT cells and dendritic cells (DCs) have been found in 
atherosclerotic lesions and their contributions to atherosclerosis has been widely 
studied (Vanderlaan and Reardon 2005). In general, macrophages and CD4+ T 
cells (Laurat, Poirier et al. 2001) comprises the largest percentage of immune cells 
found in atherosclerotic plaques and they are thought to be pro-atherogenic as 
they contribute to the inflammatory process by producing cytokines that attract 
smooth muscle cells and other lymphocytes, compromising plaque stability. 
Conversely, CD4+CD25+ regulatory T cells have been shown to protect against 
atherosclerosis (Ait-Oufella, Salomon et al. 2006).  
1.6 The role of B lymphocytes in Atherosclerosis 
1.6.1 Cellular effects of B cells in Atherosclerosis 
 B lymphocytes are found to be localized in the adventitia of the aorta near 
advanced atherosclerotic plaques in mice and humans (Zhou and Hansson 1999, 
Aubry, Riehle et al. 2004, Galkina, Kadl et al. 2006). However, their role in the 
pathogenesis of atherosclerosis remains elusive. 
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 Several studies provide evidence that B cells confer protective effects in 
murine models of atherosclerosis. A protective role of B cells was first 
investigated by Caligiuri et al, who showed that the adoptive transfer of splenic B 
cells from either WT or atherosclerotic apoE-/- mice into young recipient apoE-/- 
mice reduced atherosclerosis (Caligiuri, Nicoletti et al. 2002).  Interestingly, mice 
which received apoE-/- B cells developed fewer lesions compared to mice which 
received WT B cells, suggesting that B cells acquire increased atheroprotective 
properties in hypercholesterolemic conditions (Caligiuri, Nicoletti et al. 2002). 
The results of this study were supported by Major et al, who showed that ldlr-/- 
mice rendered B cell deficient by bone marrow transplantation from µMT mice 
developed increased atherosclerotic lesions (Major, Fazio et al. 2002). Together, 
these studies suggest a protective role of B cells in atherosclerosis. However, B 
cells have also been shown to possess pro-atherogenic properties. The depletion 
of B lymphocytes using anti-CD20 antibodies reduced the development and 
progression of atherosclerosis in apoE-/- and ldlr-/- mice through decreasing IFN-γ 
production by T cells (Ait-Oufella, Herbin et al. 2010). 
In recent years, studies have been done to elucidate the effects of B cell 
subsets on atherosclerosis. It was found that the transfer of conventional B2 cells 
but not B1 cells into B cell-deficient atherogenic mice (apoE-/- µMT-/-) augmented 
atherosclerosis (Kyaw, Tay et al. 2010). Further evidence for a pathogenic role of 
B2 cells came from studies on the role of BAFFR depletion in atherosclerotic 
mice. apoE-/-BAFFR-/- mice lacking mature B2 cells  developed decreased 
atherosclerotic lesions (Kyaw, Tay et al. 2012). In addition, the specific depletion 
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of B2 cells in apoE-/- mice using anti-BAFFR antibodies ameliorated 
atherosclerosis (Kyaw, Cui et al. 2013). Even though some B cells seem to drive 
the development of atherosclerosis, further studies in mice and humans are 
required to address the direct role of each B2 cell subset in order to provide more 
conclusive evidence on their functions in atherosclerosis.  
In contrast, the B1 cell population clearly protect against atherosclerosis 
because the adoptive transfer of B1a cells into splenectomized apoE-/- mice 
attenuated atherosclerosis. This protection was dependent on the ability of B1a 
cells to secrete IgM antibodies as the transfer of secreted IgM-/- B1a cells into 
splenectomized apoE-/- recipients failed to protect against the disease (Kyaw, Tay 
et al. 2011). 
 
1.6.2 The role of antibodies to oxidized LDL in atherosclerosis 
 The initiation of atherosclerosis involves the oxidation of LDL and oxLDL 
is thought to be highly immunogenic (Matsuura, Hughes et al. 2008). At present, 
it is hypothesized that the IgM response to oxLDL is anti-atherogenic, while the 
IgG response is pro-atherogenic (Shoenfeld, Wu et al. 2004, Binder and 
Silverman 2005, Tsimikas, Brilakis et al. 2007) 
 In humans and animal models of atherosclerosis, the titer of anti-oxLDL 
antibodies correlate with atherosclerosis lesion formation and is often used as a 
predictor for atherosclerosis development (Smook, van Leeuwen et al. 2008). 
Palinski et al. demonstrated that anti-oxLDL antibodies correlate with the 
development of aortic plaques in atherosclerotic mice (Palinski, Tangirala et al. 
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1995). In addition, immunization of mice and rabbits with oxLDL epitopes such 
as malondialdehyde-modified LDL (MDA-LDL) (a widely used model of oxLDL) 
resulted in high titers of antibodies against them and significantly reduced 
atherosclerotic lesions (Palinski, Miller et al. 1995, Freigang, Horkko et al. 1998). 
In humans, patients with cardiovascular disease have been reported to develop 
lower plasma anti-oxLDL IgM levels while high IgG antibody levels to oxLDL 
often correlate with disease severity (Tsimikas, Willeit et al. 2012). In one study, 
Salonen et al. found a positive correlation between anti-oxLDL IgG antibody 
titers and the development of carotid atherosclerosis in men (Salonen, Yla-
Herttuala et al. 1992).  
 Natural IgM antibodies against the phosphocholine epitope found on 
oxLDL (T15 IgM) have been reported to play protective roles in atherosclerosis. 
Atherosclerotic mice deficient for IL-5 showed decreased secretion of T15 IgM 
antibodies and aggravated atherosclerosis (Binder, Hartvigsen et al. 2004). It was 
also reported that IL-5 levels are positively related to plasma levels of anti-oxLDL 
IgM antibodies and reduced subclinical atherosclerosis (Sampi, Ukkola et al. 
2008). A number of potential mechanisms on how T15 IgM antibodies may 
protect against atherosclerosis have been proposed. T15 IgM antibodies may bind 
to oxLDL and block its internalization via scavenger receptors on macrophages, 
preventing the formation of pathogenic foam cells (Horkko, Bird et al. 1999, 
Febbraio, Podrez et al. 2000). Alternatively, T15 IgM antibodies inhibit plaque 
burden by preventing the accumulation of apoptotic cells in atherosclerotic lesions 
through the binding of phosphocholine found on oxidized phospholipids present 
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on apoptotic cell surfaces (Chang, Bergmark et al. 1999). T15 IgM may also 
function to neutralize the proinflammatory properties of oxidized phospholipids 
found on apoptotic cells and oxLDL, inhibiting endothelial cell activation and 
induction of cell death at the vessel wall (Huber, Vales et al. 2002, Miller, Choi et 
al. 2011). In contrast, oxLDL IgG binding to oxLDL promotes the uptake of the 
complex by phagocytic cells via FC-γ receptors, facilitating the formation of foam 
cells which aggravates atherosclerosis (Khoo, Miller et al. 1992). 
 
1.7 The Spleen 
 The spleen is the largest lymphoid organ in mammals. It comprises of two 
major components, the red and the white pulp. The red pulp functions to filter the 
blood and remove old erythrocytes. Plasmablasts and plasma cells localized in the 
red pulp allows for rapid entry of antibodies into the bloodstream. The spleen is 
the major organ for sampling blood borne antigens. Cells and antigens enter the 
spleen through the splenic artery, which branches into central arterioles that 
terminate in the red pulp. Central arterioles branch into smaller follicular 
arterioles in the white pulp, which direct systemic blood flow into the marginal 
sinus (Figure 1.3). The white pulp is organized into lymphoid compartments 
where chemokine-driven T and B cell homing, maturation and activation occurs. 
Splenic T and B cells form distinct areas called the T cell zone or periarteriolar 
lymphoid sheath (PALS) and the B cell follicles respectively. Located within the 
follicles are mature resting B cells called Follicular (FO) B cells that surround 
clusters of follicular dendritic cells. The PALS and B cell follicles are surrounded 
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by the marginal zone, which consists of a large number of resident cells including 
macrophage subsets, dendritic cells and MZ B cells (Kraal 1992, Mebius and 
Kraal 2005, Kraal and Mebius 2006) (Figure 1.3). 
 
Figure 1.3 Structure of the spleen. Different compartments of the mouse spleen 
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1.8 B lymphocyte subsets 
 B cells can be divided into two major lineages - B1 cells that arise from 
fetal liver precursors and are particularly dominant in the peritoneal and pleural 
cavities, and B2 cells that originate from bone marrow-derived precursors and are 
enriched in secondary lymphoid organs (Welner, Pelayo et al. 2008). The main 
B2 cell populations include FO B cells and MZ B cells. 
1.8.1 Follicular B Cells 
 FO B cells are a subset of recirculating, long-lived mature B cells which form 
the bulk of B cells in the follicles of the spleen. They express high levels of IgD and 
CD23 and low levels of IgM and CD21. Naive FOB cells residing in the follicles may 
present T-dependent antigens to activate T cells, become activated, expand and 
differentiate into short-lived plasma cells (Allman and Pillai 2008). Plasma cells 
formed in this extrafollicular response provide an immediate defense against 
pathogens. Activated FO B cells may migrate into B cell follicles to take part in the 
germinal center (GC) reaction, giving rise to short lived plasma cells that secrete 
antigen specific germ line encoded antibodies and memory B cells (LeBien and 
Tedder 2008).   
1.8.2 Marginal Zone B Cells 
1.8.2.1 Phenotype of MZ B cells 
 MZ B cells are a unique subset of non-recirculating, long-lived B cells 
which populate the splenic MZ where they represent 5% of total splenic B cells. 
They express high levels of IgM and low levels of IgD and CD23 (Oliver, Martin 
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et al. 1997, Oliver, Martin et al. 1999). They also express high levels of the 
complement receptor type II CD21, a non classical major histocompatibility 
complex (MHC) Class I molecule CD1d and scavenger receptor CD9 (Oliver, 
Martin et al. 1999). MZ B cells exhibit a pre-activated state and are faster and 
more efficient than FO B cells in the capture, processing and presentation of 
antigen as well as delivering co-stimulatory signals to T cells (Oliver, Martin et al. 
1999) due to higher basal levels of MHC class II, CD80 and CD86 (Attanavanich 
and Kearney 2004).  
1.8.2.2 Functional properties of MZ B cells 
 MZ B cells are strategically positioned next to the marginal sinuses, 
allowing them to respond rapidly to blood-borne bacteria pathogens (Pillai, 
Cariappa et al. 2005). Upon interaction with antigens exposed on antigen 
presenting cells, MZ B cells rapidly differentiate into short-lived plasmablasts that 
secrete large amounts of IgM via either an extrafollicular T cell-independent 
pathway or T cell dependent pathway (Martin, Oliver et al. 2001, Song and Cerny 
2003, Chappell, Draves et al. 2012).  In particular, they have been functionally 
linked to immune responses against Type-2 T-independent (TI-2) antigens such as 
phosphorylcholine (PC) found on oxLDL and many pathogenic bacteria  MZ B 
cells can also generate long-lived plasma cells that secrete high affinity antibodies 
via a canonical follicular T dependent pathway involving the presentation of 
peptide-MHC class II complexes to CD4+ T helper cells. In addition to inducing 
IgM production, MZ B cells may also produce IgG or IgA via class switch 
recombination (MacLennan, Toellner et al. 2003, Puga, Cols et al. 2012). While 
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IgM is required for the neutralization and complement-mediated killing of 
microorganisms, IgG and IgA amplify the phagocytosis and killing of opsonized 
microorganisms, providing MZ B cells with additional effector functions (Cerutti, 
Cols et al. 2013). 
  
MZ B cells have polyreactive B cell receptors (BCRs) that recognize 
conserved molecular signatures shared by foreign and autologous antigens 
(Bendelac, Bonneville et al. 2001, Martin and Kearney 2002). MZ B cells play a 
role as innate sensors in immune responses due to their high expression of toll-
like receptors (TLRs) (Genestier, Taillardet et al. 2007, Treml, Carlesso et al. 
2007, Rubtsov, Swanson et al. 2008). In response to TLR agonists, MZ B cells 
proliferate and mature, increasing their expression of MHC Class II, CD40, CD86 
molecules and secrete antibodies (Rubtsov, Swanson et al. 2008). Dual BCR and 
TLR engagement generates signals that results in the extensive production of low 
affinity antibodies by MZ B cells, bridging the temporal gap required for the 
production of high affinity antibodies by FO B cells (Pone, Zhang et al. 2012). 
Dysregulated engagement of the BCR and TLRs by self antigens results in the 
pathogenic activation of autoreactive MZ B cells which contribute to the onset of 
autoimmunity (Rawlings, Schwartz et al. 2012).   
MZ B cells are able to promote optimal immune responses by interacting 
with other cell types. For instance, they can transport and deposit IgM-containing 
immune complexes onto follicular DCs (FDCs) (Ferguson, Youd et al. 2004), or 
process antigen for direct presentation on MHC Class II molecules to activate 
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CD4+ T cells (Martin and Kearney 2002). In addition, MZ B cells have the 
potential to condition iNKT cell functions in vivo. MZ B cells express high levels 
of the non-classical class I molecule CD1d, which allows them to present lipid 
antigens to iNKT cells and activate them (Bialecki, Paget et al. 2009). Upon 
activation, iNKT cells produce large amounts of cytokines, including IFN-γ and 
IL-4 that leads to downstream activation of DC, NK cells, B cells and 
conventional T cells (Bendelac, Savage et al. 2007). As such, the MZ B cell/iNKT 
cell interaction may play important roles in the immune system. This will be 
further discussed in a later section. 
1.8.2.3 Innate signals required for MZ B cell homing 
 In mice, MZ B cells are confined to the MZ of the spleen and do not 
recirculate, as compared to FO B cells. MZ B cells express high levels of 
sphingosine 1 phosphate (S1P) receptors (S1P1 and S1P3), which binds to the 
lysophospholipid S1P that is found at high concentrations in the blood passing 
through the MZ (Cinamon, Matloubian et al. 2004).  MZ B cells are prevented 
from entering the follicles due to signaling from S1P receptors which overwrites 
the powerful attraction of B cells towards the follicles that is mediated by CXCR5 
in response to CXCL13 produced by FDCs (Cinamon, Zachariah et al. 2008). The 
retention of MZ B cells in the MZ also requires the interaction of αLβ2 (LFA-1) 
and α4β1 (VLA4) integrins expressed on MZ B cells with intracellular adhesion 
molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1), 
respectively, on stromal cells (Lu and Cyster 2002). MZ B cells receive further 
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retention signals from MARCO, a scavenger receptor expressed by MZMs. 
(Karlsson, Guinamard et al. 2003). 
1.9 Human MZ B cells 
 Human MZ B cells share many common properties with their murine 
counterparts but there are also striking differences in their localization and 
physiological properties. In humans, splenic MZ B cells are identified by their 
IgMhi IgDlo CD1c+ CD21hi CD23- CD27+ phenotype and they can be found in 
multiple locations including the lymph nodes, tonsils, Peyer’s patches, blood and 
spleen (Weill, Weller et al. 2009). In contrast to murine MZ B cells, human MZ B 
cells have the ability to extensively recirculate and are not confined to the splenic 
MZ (Weller, Braun et al. 2004, Weill, Weller et al. 2009). Similarly to mouse MZ 
B cells, human MZ B cells may be able to take part in both T-independent 
responses against microbial polysaccharides as well as T-dependent responses to 
microbial proteins, resulting in the production of IgM, IgG and IgA antibodies 
(Weill, Weller et al. 2009). 
1.10 Marginal Zone B Cell Development 
 In mice, MZ B cells and FO B cells arise from bone marrow precursors 
via transitional B cells.  
 B cells develop from hematopoietic stem cells (HSC) in the bone marrow. 
Successful rearrangement of immunoglobulin heavy chain (IgH) gene segments in 
pro-B cells lead to precursor (pre-B) cells which express the pre-B-cell receptor 
(pre-BCR) consisting of an Igµ heavy chain and surrogate light chains (Shapiro-
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Shelef and Calame 2005). Naive immature B cells that survive negative selection 
leaves the bone marrow and continue their development in the spleen, where they 
pass through transitional stages T1 and T2 (Shapiro-Shelef and Calame 2005). 
Most T2 B cells mature into naïve long-lived FO B cells while a small proportion 
of transitional B cells mature to become MZ B cells that homes to the splenic 
marginal zone (Shapiro-Shelef and Calame, 2005) (Figure 1.4). 	  
	  
1.11 Lineage commitment to Marginal Zone B Cells   
1.11.1 Notch 2 Signaling and MZ B cell development 
 Notch 2 signaling is one of the major driving forces for normal MZ B cell 
development. Notch 2 belongs to a group of four Notch receptors that influence 
cell fate decisions by regulating transcription during lymphocyte development 
(Allman, Punt et al. 2002). Delta Like 1 (DL1) is a transmembrane protein which 
serves as the ligand for Notch 2. It is expressed by DCs, macrophages and stromal 
cells found in the red pulp and MZ of the spleen (Tan, Xu et al. 2009).  
 Notch 2 signaling is initiated by DL1 binding which induces the 
proteolytic release of the intracellular portion of Notch (ICN) from the cell 
membrane. ICN, RBP-Jk and Mastermind proteins form a ternary complex that 
activates Notch 2 target genes. Mice lacking Notch 2 or RBP-Jk in B cells, 
Mastermind-like 1 (MAML) or DL1 have defects in MZ B cell development 
(Tanigaki, Han et al. 2002, Saito, Chiba et al. 2003, Hozumi, Negishi et al. 2004, 
Oyama, Harigaya et al. 2007, Wu, Maillard et al. 2007). This highlights an 
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important role for Notch 2 signaling in the development of MZ B cells in the 
spleen. 
 Notch 2 signaling can be suppressed by binding of MSX2-interacting 
protein (MINT) to RBP-J which competes with ICD, preventing the formation of 
the ternary complex required for the transcription of Notch 2 target genes. High 
levels of MINT blocks differentiation of precursor B cells into MZ B cells and FO 
B cells develop preferentially. Mice in which MINT is inactivated have an 
increased number of MZ B cells, suggesting that Notch 2 signaling favors an 
increase in MZ B cell development (Kuroda, Han et al. 2003) (Figure 1.4).  
1.11.2 Helix Loop Helix Proteins E2A and ID proteins regulate MZ B/ FO B cell 
fate 
 Although it is still uncertain as to how Notch mediated gene regulation 
contribute to MZ B cell development, a possible involvement of helix-loop-helix 
proteins and Notch signaling has been suggested to be a contributing factor. E2A 
is a helix-loop-helix transcription factor and ID2 and ID3 proteins oppose E2A 
activity. E2A+/- mice show an increase in levels of MZ B cells whereas FO B cell 
numbers decrease (Quong, Martensson et al. 2004).  High E2A activity favors the 
development of FO B rather than MZ B cell development. In contrast, induction 
of ID3 expression promotes MZ rather than FO B cell development (Murre 2005) 
(Figure 1.4). 
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Figure 1.4 Notch 2 signaling and Helix loop helix proteins can affect MZ B 
cell and FO B cell development. Immature B cells leave the bone marrow and 
continue their development in the spleen where they pass through 2 transitional 
stages. Binding of DL1 to Notch 2 receptor favors MZ B cell development. MINT 
inhibits Notch 2 signaling and favors FO B cell development. ID2/3 proteins 
promotes MZ B cell differentiation while E2A facilitates FO B cell differentiation.  
 
1.11.3 Fli-1 regulates MZ B and FO B cells development 
Friend leukemia integration 1 transcription factor (Fli-1) is a member of 
the E26 transformation specific (Ets) transcription family and is expressed in 
haematopoietic cells (Ben-David, Giddens et al. 1991, Watson, Smyth et al. 1992). 
Examination of spleens from Fli-1 deficient mice demonstrated that the 
percentage of FO B cells was significantly decreased while transitional B cells 
and MZ B cells were significantly increased (Zhang, Moussa et al. 2008). Thus, 
Fli-1 is a negative regulator of MZ B cell development and a positive regulator of 
FO B cell development (Zhang, Moussa et al. 2008). The diagram below explains 
how Fli-1 deficiency may result in an increase in MZ B cells. Fli-1 binds to mb-1 
promoter, which encodes the transmembrane signaling protein Ig-α, an important 
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component of the BCR (Figure 1.8). A deficiency in Fli-1 leads to decreased 
binding to mb-1 promoter (Zhang, Moussa et al. 2008). Consequently, there is 
reduced expression of Ig-α which results in decreased intracellular Ca2+ flux 
following BCR cross linking. This reduced expression may contribute to weak B 
cell receptor signaling and a concomitant decrease in the number of FO B cells 
and an increase in the number of MZ B cells (Niiro and Clark 2002, Pillai, 
Cariappa et al. 2005). Fli-1 has also been reported to regulate the expression of 
anti-apoptotic protein BCL-2 which is involved in the development of MZ B cells 
and FO B cells (Pereira, Quang et al. 1999, Lesault, Quang et al. 2002). BCL-2 
transgenic mice lack MZ B cells while BCL-2 knockout mice have an increased 
number of MZ B cells (Brunner, Marinkovic et al. 2003). Thus, Fli-1 deficiency 
results in decreased expression of BCL-2, which contributes to an increase in MZ 
B cells (Figure 1.5). 
 
Figure 1.5 Diagram showing how Fli-1 deficiency may influence MZ B cells 
and FO B cells development 
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1.12 Marginal Zone B Cell Survival 
1.12.1  BAFF/BAFFR signaling is crucial for MZ B cells survival 
 The tumour necrosis factor (TNF)-family member B cell activating factor 
(BAFF) is a homotrimer that is found either on the cell surface as a type II 
transmembrane protein or is released from cells as a soluble ligand (Mackay, 
Schneider et al. 2003, Mackay, Silveira et al. 2007). BAFF is produced by 
macrophages, monocytes, DCs and T cells where it functions as a crucial survival 
factor for peripheral B cells. (Schneider, MacKay et al. 1999, Nardelli, Belvedere 
et al. 2001). BAFF receptor (BAFFR) is expressed by the transitional 2, MZ and 
FO mature conventional B2 cell populations. Stimulation of BAFFR potently 
activates the alternative NF-ĸB2 pathway and weakly activates the classical NF-
kB1 pathway in primary B cells (Mackay and Schneider 2008). Both NF-ĸB 
pathways are required for B cell survival, which can be sustained by signaling 
through BAFFR alone (Mackay and Schneider 2008). NF-ĸB activation 
downstream of BAFF has been linked to increased expression of anti-apoptotic 
proteins such as the Bcl-2 family members and to integrin mediated localization 
of B cells in the MZ, which further contributes indirect survival signals through 
integrin mediated Akt activation (Enzler, Bonizzi et al. 2006, Mackay and 
Schneider 2008).  
 The importance for BAFF and BAFFR in the survival of B cells during B 
cell maturation was demonstrated in BAFF and BAFFR-deficient animals, in 
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which maturation of MZ B cells and B2 cells is impaired beyond the T1 B cell 
developmental stage (Mackay, Schneider et al. 2003).  
1.12.2 BAFF producing cells in the spleen- Splenic Dendritic cells 
 DCs are sparsely but widely distributed cells of haematopoietic origin that 
are specialized for the uptake, processing and presentation of antigens to T cells 
(Steinman 1991, Hart 1997). In mice, splenic DCs are termed conventional DCs 
(cDCs) and have been further subdivided into CD8α+ DCs and CD4+ CD11b+ 
DCs (Schlitzer and Ginhoux 2014). CD8α+ cDCs are localized to the white pulp 
area in close proximity to T cells and are phenotypically classified as CD11chigh 
CD11blow/- MHC Class IIhigh cells (Hey and O'Neill 2012). In mice, the CD8α+ 
cDCs primes naïve CD4 T cells to make Th1 cytokines. They are also important 
for the cross presentation and stimulation of CD8+ T cells through IL-12 secretion, 
which promotes Th1 differentiation (Mashayekhi, Sandau et al. 2011). CD4+ 
CD11b+ cDCs are localized in the red pulp and MZ of the spleen and are 
phenotypically classified as CD11chigh MHC Class IIhigh cells (Hey and O'Neill 
2012). They function to prime naïve CD4 T cells to make Th2 cytokines and have 
weaker cross priming ability (De Smedt, Pajak et al. 1996). DCs may also provide 
critical survival signals to antigen specific MZ B cells and promote their 
differentiation into IgM-secreting plasmablasts (Balazs, Martin et al. 2002). 
Recent studies have also suggested a role for CD11b+ DCs in the induction of 
Th17 responses (Plantinga, Guilliams et al. 2013). 
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1.12.3 BAFF producing cells in the spleen- Splenic Macrophages 
 Macrophages are highly heterogenous cells that phagocytose and process 
foreign materials, dead cells and debris. The spleen contains subpopulations of 
macrophages known as Red Pulp macrophages (RPM), Marginal Zone 
Macrophages (MZM) and Metallophilic macrophages. These macrophages are 
subdivided based on their anatomical location and functional phenotype (Davies, 
Jenkins et al. 2013).  
1.12.3.1 Red Pulp Macrophages 
 In the mouse, RPMs are identified through their expression of F4/80+ 
CD11blow/- CD206+ phenotype and selectively express the transcription factor Spi-
C (Kohyama, Ise et al. 2009). They function to phagocytose aged erythrocytes as 
they pass through the red pulp (Mebius and Kraal 2005). 
1.12.3.2 Marginal Zone Macrophages (MZM) & Metallophilic Macrophages 
 The outer layer of the MZ consists of a specialized type of macrophage 
known as MZMs, which express high levels of scavenger and pattern recognition 
receptors such as scavenger receptor A, macrophage receptor with collagenous 
structure (MARCO) and SIGN-R1 (a Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) homolog) (Elomaa, 
Kangas et al. 1995, Geijtenbeek, Groot et al. 2002, Kang, Kim et al. 2004, Lanoue, 
Clatworthy et al. 2004). MZMs have been shown to regulate the retention of MZ 
B cells, a process which requires MARCO (Karlsson, Guinamard et al. 2003). 
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 The metallophilic macrophages form a distinct rim of cells at the border of 
the marginal zone situated at the margin of the white pulp along the inner border 
of the marginal sinus. These macrophages are involved in scavenging pathogens 
and apoptotic cells and can be identified by their expression of Moma-1 (CD169) 
(Kraal 1992, Kraal and Mebius 2006).  
 MZM and metallophilic macrophages act in immune surveillance and are 
well positioned to capture blood borne antigens for regulating subsequent 
adaptive immune responses (Taylor, Martinez-Pomares et al. 2005, den Haan and 
Kraal 2012). 
1.12.4 Excessive BAFF production promotes MZ B cell expansion 
 BAFF signaling is important for promoting B cell survival from the T2 B 
cell stage (Mackay, Woodcock et al. 1999, Sasaki, Derudder et al. 2006). BAFF 
transgenic mice which exhibit elevated BAFF production, develop an expanded 
MZ B cell compartment (Mackay, Woodcock et al. 1999). 
In the mouse spleen, BAFF producing cells such as DCs, monocytes and 
macrophages may contribute to excessive BAFF production, resulting in an 
expansion of the MZ B cell compartment. As MZ B cells possess APC attributes, 
they may potently activate naïve T cells (Mackay and Schneider 2009). Upon 
activation, T cells up-regulate BAFFRs and secrete BAFF. Binding of BAFF to 
BAFFR speeds up proliferation and differentiation of T cells into effector cells 
(Ng, Sutherland et al. 2004, Groom and Mackay 2008). This further contributes to 
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Figure 1.6 Excess BAFF production promotes MZ B cell expansion. DCs, 
monocytes and macrophages are the main BAFF producing cells in the spleen. 
Excess BAFF production results in MZ B cells expansion. MZ B cells may 
present antigen to activate T cells. Activated T cells up-regulates BAFFR and 
secretes BAFF, which speeds up and favor the differentiation into Th1 cells that 
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1.13 Marginal Zone B cells in autoimmunity and atherosclerosis 
Autoimmune diseases are often associated with chronic inflammation and 
immune dysregulation, which may lead to dyslipidemia, vascular dysfunction, 
atherosclerotic lesions and autoantibody production (Shoenfeld, Gerli et al. 2005, 
Artenjak, Lakota et al. 2012). Thus, atherosclerosis, a chronic inflammatory 
disease of the arteries is also considered an autoimmune disease. Autoimmune 
diseases are a result of the break down of tolerance to self-antigens. As multi-
reactive MZ B cells are allowed to persist, they may potentially initiate 
autoimmunity when recognizing self-molecules. However, the contribution of MZ 
B cells to autoimmune pathogenesis is still debated, and to date no clear 
relationship has been made between the expansion of MZ B cells and autoimmune 
diseases. Many mouse models of lupus, however, are associated with an 
expansion of MZ B cells. NZB/NZW F1 mice exhibited an expanded MZ B cell 
compartment and the treatment of these mice with anti-CD1 mAbs decreased the 
production of autoantibodies and ameliorated the development of lupus (Zeng, 
Lee et al. 2000). In a mouse model of estrogen induced lupus, estrogen treatment 
increased the MZ B cell numbers and promoted the secretion of anti-DNA 
antibodies (Grimaldi, Michael et al. 2001). Several studies have also shown that 
weakly auto-reactive B cells are enriched in the MZ and partially auto-reactive 
anti-dsDNA specific B cells are present in the MZ B cell pool. In addition, weakly 
auto-reactive MZ B cells in mice transgenic for glucose-6-phosphate isomerase 
(GPI) secreted GPI specific IgM antibodies spontaneously (Mandik-Nayak, Racz 
et al. 2006). Furthermore, MZ B cell activation and expansion partially 
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contributed to the development of type 1 diabetes in NOD mice (Bashratyan, 
Sheng et al. 2013). However, the elimination of MZ B cells in mice with B cells 
that overexpress TLR7 led to the development of autoantibodies that aggravated 
lupus disease (Hwang, Lee et al. 2012). In addition, MZ B cells may confer 
protective effects in certain autoimmune diseases through the secretion of IL-10 
(Lenert, Brummel et al. 2005, Hussain and Delovitch 2007). Collectively, the 
weakly auto-reactive nature of MZ B cells may promote autoimmunity through 
their ability to spontaneously secrete autoantibodies but the contribution of MZ B 
cells in autoimmune diseases appear to be dependent on the nature of the 
autoimmune model.  
 
1.14 Invariant Natural Killer T (iNKT) cells 
1.14.1Phenotype and localization of iNKT cells 
 Type 1 Natural Killer T Cells or iNKT cells are a distinct population of T 
cells that are CD1d restricted (Bendelac, Savage et al. 2007). They co-express cell 
surface molecules of both natural killer cells (NK1.1) and a semi-invariant T-cell 
receptor (TCR) α chain (Vα14-Jα18 in mice) paired with a limited set of TCR β 
chains (Vβ8.2, Vβ7 or Vβ2) and can be found predominantly in the blood, spleen 
and liver where they represent approximately 0.5%, 1-2% and 20-30% of 
lymphocytes respectively (Benlagha, Weiss et al. 2000, Godfrey, MacDonald et al. 
2004, Kronenberg 2005). In mice, two major subsets of iNKT cells exist, a 
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CD4+CD8- and CD4-CD8- double negative (DN) population (Seino and Taniguchi 
2005).  
1.14.2 CD1d and iNKT cell ligands 
 CD1d is a conserved, non-polymorphic major histocompatibility complex 
(MHC) class I-like molecule expressed by many antigen presenting cells (APC) 
including DCs, macrophages and MZ B cells (Brossay, Jullien et al. 1997, Roark, 
Park et al. 1998). The first CD1d-presented lipid antigen for iNKT cells, α-
galactosylceramide (α-GalCer), is a specific and potent glycolipid isolated from a 
marine sponge (Kawano, Cui et al. 1997). Fluorescently labeled CD1d tetramers 
loaded with α-GalCer have greatly facilitated the identification and study of iNKT 
cells (Benlagha, Weiss et al. 2000, Matsuda, Naidenko et al. 2000). 
1.14.3 iNKT cell activation 
 iNKT cells have an activated/memory phenotype and are unique in their 
ability to respond to glycolipid antigens presented on CD1d. Upon activation, 
iNKT cells are able to rapidly secrete large amounts of both pro and anti-
inflammatory cytokines such as IFN-γ and IL-4 respectively. This allows for a 
wide range of regulatory potential by other cells of the immune system such as 
neutrophils, B cells, DCs and conventional T cells, thus polarizing the immune 
response so that the effects may not always be directly due to the action of iNKT 
cells themselves (Gumperz, Miyake et al. 2002). 
 iNKT cells may be activated to perform effector functions via three 
different pathways. The first is an indirect pathway induced by microbial Toll-like 
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receptor (TLR) ligands (lipopolysaccharide, single stranded RNA and 
demethylated CpG DNA fragments) activates the release of proinflammatory 
cytokines IL-12 and IL-18 by APCs, which in turn induce the production of IFN-γ 
by iNKT cells (Nagarajan and Kronenberg 2007). This bystander activation is 
independent of cognate CD1d interaction by the invariant TCR. The second 
pathway involves direct endogenous activation where iNKT cells recognize 
unknown endogenous antigens presented on CD1d. The biosynthesis of the 
endogenous agonist ligands is induced and/or upregulated in DCs after 
stimulation of TLR signaling. Low affinity interaction between the invariant TCR 
and endogenous lipid-CD1d complex may still need costimulation by the 
inflammatory cytokine IL-12 produced by DCs to induce iNKT cell effector 
functions. The third pathway involves direct exogenous activation where iNKT 
cells recognize exogenous CD1d-restricted lipid antigens presented on CD1d. The 
exogenous lipids are internalized by DCs, being processed and loaded onto CD1d. 
This class of iNKT cell ligands are strong agonists capable of eliciting effector 
functions independently of costimulation by DC derived inflammatory cytokines 
(De Libero, Macdonald et al. 2007) (Figure 1.7).  
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Figure 1.7 Three pathways of activation for iNKT cells. a) Indirect activation b) 
Direct endogenous activation c) Direct exogenous activation Figure adapted from 
(De Libero, Macdonald et al. 2007).
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1.14.4 iNKT cells in atherosclerosis 
 iNKT cells have been found in the shoulder region of human carotid artery 
plaques (Bobryshev and Lord 2005) as well as in human atherosclerotic tissue 
derived from abdominal aortic aneurysms (Chan, Pejnovic et al. 2005). In 
addition, several approaches have been taken to elucidate the role of iNKT cells in 
atherosclerosis using genetically modified mouse models of the disease. Studies 
using CD1d deficient mice which lack iNKT cells provide evidence that iNKT 
cells are pro-atherogenic. For instance, CD1d-/- apoE-/- mice showed a significant 
reduction of atherosclerotic lesions in the aortic root (Nakai, Iwabuchi et al. 2004, 
Tupin, Nicoletti et al. 2004). A reduction in aortic lesion formation was also 
observed in Ldlr-/- mice transplanted with CD1d-/- bone marrow, further 
confirming that iNKT cells were responsible for increasing aortic lesion formation 
in mouse models (Nakai, Iwabuchi et al. 2004). In addition, eliminating iNKT 
cells using a targeted deletion of the Jα18 gene in Ldlr-/- mice reduced the 
formation of early atherosclerotic lesions (Rogers, Burchat et al. 2008). The 
importance of iNKT cells in atherosclerosis was also highlighted in studies 
demonstrating that the repeated activation of iNKT cells by the glycolipid α-
GalCer led to an increase in aortic lesion formation in Ldlr-/- and apoE-/- mice 
(Major, Wilson et al. 2004, Nakai, Iwabuchi et al. 2004, Tupin, Nicoletti et al. 
2004). Splenocytes from Vα14tg mice which overexpress iNKT cells were 
adoptively transferred into immune deficient mice (Ldlr-/- Rag-/-), resulting in an 
increase in the formation of aortic root lesions (VanderLaan, Reardon et al. 2007). 
An adoptive transfer study using different subsets of iNKT cells transferred to 
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apoE-/- mice showed that CD4+ iNKT cells are the subset responsible for the pro-
atherogenic activity due to their increased ability to secrete pro-inflammatory 
cytokines such as IFN-γ, TNF-α and IL-2 upon α-GalCer stimulation (To, Agrotis 
et al. 2009). 
1.14.5 Model of iNKT cells providing B cell help during antibody responses   
 
Figure 1.8 Possible interactions between B cells and iNKT cells.  
 
 iNKT cells can provide cognate help for lipid specific B cells that express 
CD1d. Glycolipid antigens captured by the LDLR or BCR are loaded onto 
intracellular CD1d and presented on the cell surface as CD1d/antigen complexes. 
Recognition of CD1d/antigen complexes by the TCR on the iNKT cell, coupled 
with the engagement of co-stimulatory molecules CD40 and B7 molecules are 
important for cognate iNKT cell help for B cell antibody and proliferation 
responses to lipid antigens (Leadbetter, Brigl et al. 2008, Lang 2009). However, 
conflicting studies have shown that iNKT cells can inhibit B cell proliferation and 
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promote death of B cells through activation induced cell death (AICD) in a partly 
contact dependent manner (Wen, Yang et al. 2011). The cytokines responsible for 
inducing death of B cells upon iNKT cell activation have not been identified but it 
is possible that IFN-γ may play a role (Figure 1.8).  
Recently, a sub-population of BCL-6 expressing iNKT cells with 
characteristics of Follicular helper T cells (TFH) was found to provide CD1d-
dependent cognate B cell help (Chang, Barral et al. 2012). Interaction of the TCR 
on the iNKT cell and CD1d-lipid antigen complex on the B cell surface results in 
IL-21 secretion, rapid IgG production and some affinity maturation, but does not 
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1.15 Objectives of study 
 Numerous studies have provided evidence suggesting that the expansion 
of certain B lymphocyte subsets such as MZ B cells contribute to the pathogenesis 
of autoimmune disorders such as lupus and diabetes. Interestingly, a similar 
expansion of the MZ B cell compartment was observed in atherosclerotic apoE-/- 
mice. In this thesis, we elucidate the underlying mechanisms involved in the 
expansion of MZ B cells in atherosclerotic apoE-/- mice and their possible 
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Chapter 2: Materials and Methods 
 
2.1 Animals 
Male apoE-/- mice on a C57/BL6 background were obtained from The Jackson 
Laboratory (Bar Harbor, ME). CD45.2 male WT mice on a C57/BL6 background 
were purchased from the Centre for Animal Resources (National University of 
Singapore) and were matched for age and diet. Animals were maintained on a 
regular chow diet or switched at 6 weeks of age to a high fat, rich cholesterol diet 
(21% fat and 0.2% cholesterol) (Harlan Teklad) until sacrifice. All mice were 
housed under specific pathogen free conditions with unrestricted access to food 
and water in the animal housing unit of the National University of Singapore. All 
studies done were approved by the Institutional Animal Care and Use Committee 
(IACUC). 
2.2 Blood Collection 
2.2.1 Plasma collection 
Blood was collected from mice via cardiac puncture and transferred to eppendorf 
tubes containing 40µl of 500mM anti-coagulant ethylenediaminetetraacetic acid 
(EDTA) (Sigma). The tubes were mixed and centrifuged at 14000rpm for 20 mins 
at 4°C. Plasma was collected by removing the supernatant and stored at -80°C 
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2.2.2 Serum collection 
Blood was collected by cheek bleeding of mice and transferred to Eppendorf 
tubes. The tubes were left at room temperature for 30 mins to allow clotting of 
blood and centrifuged at 14000rpm for 20 mins at 4°C. Serum was collected by 
removing the supernatant and stored at -80°C until further use. 
 
2.3 Cholesterol quantification 
Plasma samples were collected via cardiac-puncture and total cholesterol was 
determined using Cholesterol/Cholesteryl Ester Quantification Kit K603-100 (Bio 
Vision). Plasma samples from WT and apoE-/- mice were diluted 50x and 200x 
respectively with Cholesterol Reaction Buffer. 25µl of diluted samples were loaded 
into a 96-well flat bottom plate. 25 µl of reaction mix containing 22 µl of cholesterol 
reaction buffer, 1 µl of cholesterol probe, 1 µl of enzyme mix and 1 µl of cholesterol 
esterase were added to the samples and standards, incubated for 60 minutes at 37°C 
in dark conditions. After incubation, absorbance at O.D. 570nm was measured for all 
samples and standards. Values obtained were used to plot a standard curve to 
determine total cholesterol levels in the samples. 
2.4 Evaluation of lipid accumulation in the aorta by Oil Red O staining 
To evaluate atherosclerotic lesions, the whole aorta was perfused with 1xPBS and 
2% paraformaldehyde before removal from the heart. The aorta was fixed in 2% 
PFA for 24 hours, washed 3 times with 1xPBS and stained with a fat soluble dye 
oil red O (Sigma) which stain lipids red. 
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2.5 Isolation of cells from spleen 
Single cell suspensions from spleens were obtained by teasing and pressing 
tissues with 27G needles and pushing them through a 70µm cell strainer (BD 
Falcon) with a 5ml syringe core in Hanks Balanced Salt Solution (HBSS) 
containing sodium bicarbonate, without Ca2+ and Mg2+ (Sigma Aldrich). If 
isolation of DCs was required, spleens were predigested enzymatically in 1mg/ml 
of Collagenase D (Roche Diagnostics), 0.2mM EDTA (Sigma), 2% FBS in HBSS 
at 37°C for 25 mins. EDTA was added to a final concentration of 10mM and 
incubated at 37°C for 5mins to stop the digestion. Erythrocytes were lysed with 
5ml of 0.9% ammonium chloride; pH 7.2-7.6 for 5 minutes. The cells were 
washed twice with modified HBSS (containing sodium bicarbonate, without Ca2+ 
and Mg2+) (Sigma-Aldrich) and the resulting pellet was resuspended in an 
appropriate volume of FACS staining buffer (0.5% BSA and 2mM EDTA diluted 
in 1xPBS) for counting. Total number of cells was determined using a 
hemocytometer and dead cells were excluded by Trypan Blue (Sigma-Aldrich) 
staining. 
2.6 Flow cytometry 
2.6.1 Surface staining of cells for FACS analysis 
Single cell suspensions were first seeded into a 96-well round bottom plate at a 
concentration of 5x106 cells/ml. The cells were then stained in 50µl of FACS 
staining buffer containing fluorochrome conjugated primary or appropriate 
isotype control antibodies. The list of antibodies used are listed in Appendix 2. 0.5 
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µg of FcR block per million cells (1 µl of 0.5 mg/ml stock per million cells) was 
added to cells where allowed, to prevent non-specific binding of antibodies to Fc 
receptors. Cells were fixed in 1% formalin if required. T1, T2 MZP and MZ B cells 
were sorted using a MOFLO cell sorter (DakoCytomation) after staining with 
antibodies and used for RNA preparation in real-time PCR. 
 
2.6.2 Tetramer Staining for iNKT cells 
Fluorescently labeled tetrameric CD1d molecules loaded with αGalCer (CD1d 
tetramers) (NIH tetramer facility) were incubated with splenocytes for 20 mins at 
4°C to detect iNKT cells.  
 
2.6.3 Flow cytometry and analysis 
Flow cytometry was performed either on a FACSCalibur (BD Biosciences, San 
Diego, CA, USA) with CellQuest data acquisition and analysis software, or on a 
Cyan flow cytometer (Dako, Denmark) with Summit software. Data were 
analyzed with Flowjo software (Treestar). 
 
2.7 Ezetimibe Treatment 
To measure the effect of lowering plasma cholesterol on MZ B cell expansion, 6 
weeks male WT and apoE-/- mice on a C57/BL6 background were fed a high fat 
diet for 6 weeks. At 12 weeks of age, the mice were treated daily with ezetimibe 
(Kemprotec) via oral gavage at a dose of 5mg/kg/day dissolved in 200µl of corn 
	   39	  
oil. Ezetimibe inhibits the intestinal absorption of cholesterol and lowers plasma 
cholesterol levels through blocking NPC1L1 (Davis, Compton et al. 2001).  Mice 
continued to be fed a high fat diet during the treatment period. Total cholesterol 
levels in the plasma were monitored every 4 weeks.  
 
2.8 Immunofluorescence analysis 
All spleens were embedded in O.C.T Compound (Tissue-Tek). Serial 10µm 
cryostat sections of spleens were cut and mounted on polysine-coated slides and 
stored at -20°C. Before immunofluorescence staining, slides were dried for 1 hour 
at room temperature. Fresh tissue sections were fixed with cold acetone for 10 
minutes, then blocked using 10% bovine serum albumin for another 10 minutes to 
minimize non-specific antibody binding. For biotinylated antibodies, 
Avidin/Biotin blocking kit (Vector Laboratories) was used to block endogenous 
avidin and biotin binding sites. Tissue sections were incubated with 50-100µl of 
PBS/10% normal mouse serum containing primary antibodies in a humidified 
chamber for 1-2 hours at room temperature or overnight at 4°C. Tissue sections 
were incubated for 2 hours at room temperature if fluorescent conjugated 
antibodies were used. Slides were washed 3 times in 1xPBS. Tissue sections were 
incubated with 50-100µl of PBS/10% normal mouse serum containing secondary 
antibodies raised in different species if stained together for 2 hours in a 
humidified chamber at room temperature protected from light. Slides were 
washed for 3 times in 1xPBS before incubation with DAPI (1:20000) for 5 
minutes. Sections were mounted with mounting media (Dako Cytomation) and 
	   40	  
examined under a Carl Zeiss Imager.Z1 fluorescence microscope with 60N-C 2/3” 
0,63X AxioCam HRm camera. 
 
2.9 Enzyme Linked Immunosorbent Assay (ELISA) 
2.9.1 BAFF ELISA 
Spleens were snap frozen in liquid nitrogen and homogenized in RIPA buffer 
(Sigma Chemicals) supplemented with a protease inhibitor cocktail (Roche 
Diagnostics). Homogenates were centrifuged at 14,000g for 10 minutes, 4°C and 
supernatants were assayed using commercial BAFF ELISA kit as per 
manufacturer’s protocol. 
2.9.2 Total IgM ELISA 
96-well flat bottom plates were coated with 50 µl of sheep α mouse Ig (Chemicon) 
diluted in 1xPBS to a concentration of 5µg/ml and incubated overnight at 4°C. 
Plates were washed 3 times using PBS tween followed by 1xPBS. Plates were 
blocked by adding 200µl of casein/PBS (Thermo Scientific) and incubated for 1 
hour at 37°C. Plates were washed 3 times using PBS tween and 1xPBS. 50µl of 
standards and samples diluted in blocking buffer was added to the wells and 
incubated overnight at 4°C. Plates were washed 3 times using PBS tween and 1x 
PBS. 50µl of goat α mouse IgM HRP diluted 2500x in blocking buffer was added 
to the wells and incubated at 37°C for 1 hour. Plates were washed 3 times using 
PBS tween and 1x PBS. 50µl of TMB substrate was added to the wells and 
reaction was halted by addition of 25µl of sulphuric acid. Absorbance values were 
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read at a wavelength of 450nm using a microplate reader (Biorad) with microplate 
manager 5.2 software. 
2.9.3 LDL/oxLDL IgM ELISA 
96 well flat bottom plates were coated with 50µl of LDL or oxLDL (Biomedical 
Technologies) diluted in casein/TBS to a concentration of 10µg/ml and incubated 
overnight at 4°C. Plates were washed 3 times each with TBS/tween and 1x TBS. 
Blocking was performed by addition of 200µl of casein/TBS (Thermo Scientific) 
into the wells and incubated at 37°C for 1 hour. Plates were washed 3 times using 
TBS/tween and 1x TBS. 50µl of samples diluted in blocking buffer was added to 
the wells and incubated overnight at 4°C. Plates were washed 3 times using 
TBS/tween and 1x TBS. 50µl of goat α mouse IgM HRP diluted 2500x in 
blocking buffer was added to the wells and incubated at 37°C for 1 hour. Plates 
were washed 3 times using TBS/tween and 1x TBS. 50µl of TMB substrate was 
added to the wells and the reaction was halted by addition of 25µl of 2N sulphuric 
acid. Absorbance values were read at a wavelength of 450nm using a microplate 
reader (Biorad) with microplate manager 5.2 software. 
2.9.4 Quantification of serum IFN-γ and IL-4 by ELISA 
Serum IFN-γ and IL-4 levels were detected using commercial kits from R&D 
systems according to the manufacturer’s protocol. Briefly, 96 well flat bottom 
plates were coated with 100µl of capture antibody diluted in 1xPBS to a working 
concentration of 4µg/ml and incubated overnight at room temperature. Plates were 
washed 3 times each with PBS/tween and 1xPBS. Blocking was performed by 
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addition of 300µl of 1%BSA/PBS for 1 hour. Plates were washed 3 times each 
with PBS/tween and 1xPBS. 100µl of sample or standards diluted in 1%BSA/PBS 
(for IL-4) or 0.1%BSA,0.05%Tween20/TBS (for IFN-γ) and incubated for 2 
hours at room temperature. Plates were washed 3 times each with PBS/tween and 
1xPBS. 100µl of detection antibody was added to the wells and incubated for 2 
hours at room temperature. Plates were washed 3 times each with PBS/tween and 
1xPBS. 100µl of Strepavidin-HRP diluted 200 times was added to the wells and 
incubated in the dark for 20 mins at room temperature. Plates were washed 3 
times each with PBS/tween and 1xPBS. 100µl of TMB substrate was added to the 
wells and the reaction was stopped by addition of 50µl of 2N sulphuric acid. 
Absorbance values were read at a wavelength of 450nm using a microplate reader 
(Biorad) with microplate manager 5.2 software. 
2.10 Enzyme-Linked Immunosorbent Spot (ELISpot) 
Sheep α-mouse IgM (10µg/ml) was coated in nitrocellulose membrane plates 
(Millipore) overnight in 1xPBS at 4°C. The plates were blocked with casein in 
PBS (Thermo Scientific) for 2-4 hours before overnight incubation with sorted 
MZ B cells suspended in Roswell Park Memorial Institute (RPMI) (Sigma) 
supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin and L-
glutamate at 37°C. Cells were seeded at 800,000 per well. After incubation for 1 
day, the plate was washed 3 times using 1xPBS. 50µl of goat α mouse IgM 
diluted 2500 times in PBS with 0.5% FCS was incubated for 1 hour at 37°C. 
Plates were washed 3 times using PBS/tween and 1x PBS. 50µl of 3-amino-9-
ethylcarbazole (AEC) substrate (BD Bioscience) were added to the wells. To stop 
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color development, plates were washed with running water. Plates were dried at 
55°C in oven and images were captured and enumerated for spots using 
Immunospot Reader (CTL) with ImmunoSpot 5.0 Pro DC software. 
2.11 Cell culture 
Spleen cell suspension were cultured in complete RPMI (Sigma) supplemented 
with 10% FBS, penicillin-streptomycin and L-glutamate. Cells were seeded at 1 
million cells per well with 250µl of medium in 96-well round bottom plates for 2 
days. The supernatant was collected for analysis of IgM antibodies by ELISA. 
2.12 Real-Time PCR (RT-PCR) 
2.12.1 Extraction of total RNA for RT-PCR 
Total RNA from spleen was homogenized and extracted using TRIZOL reagent 
(Invitrogen) and NucleoSpin® RNA II kit (Macherey-Nagel) according to the 
manufacturer’s instructions. mRNA concentrations and purity were measured 
using Nanodrop 1000 Spectrophotometer (Thermo Scientific).  
 
2.12.2 Reverse transcription cDNA synthesis 
First strand cDNA synthesis was performed using TaqMan Reverse Transcription 
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Cycling conditions 
Each PCR reaction mix contained 2000ng of mRNA (15.4µl), 1µl of oligo-dt 
(1.25µM), 1µl of random hexamer (1.25µM) and 8µl of dNTPs (500µM per dNTP)  
Linearization profile 
Step Linearization Stabilization Maintaining 
 Hold Hold Hold 
Time 5 minutes 2 Infinite 
Temperature 65°C 4°C 4°C 
 
Previous Volume 25.4µl Final Concentration 
10x RT Buffer 4.00µl 1x 
25mM MgCl2 8.80µl 5.5mM 
RNase Inhibitor 20U/L 0.8µl 0.4U/µl 
Multiscribe Reverse Transcriptase 1µl 1.25U/µl 












Time 10 minutes 30 minutes 5 minutes Infinite 
Temperature 25°C 48°C 95°C 4°C 
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2.13.3 Primer Design 
Primers were designed using GeneQuest v7.0.0 (DNA Star) or Primer Blast on the 
NCBI website. Primer sequences for the targeted genes are listed in Appendix 4. 
2.12.4 Quantification of BAFF, IL-21 and DL-1 mRNA in the spleen by RT-
PCR 
Real-time polymerase chain reactions (RT-PCR) were performed in triplicates on 
a 7500 Real-Time PCR System (Applied Biosystems). Each RT-PCR contained 
10µl of iTaq SYBR Green supermix with ROX (Biorad), 250nM forward and 
reverse primers, 7µl of RNase free water and 1µl of cDNA template. The cycling 
conditions for all genes were: denaturation at 95°C for 10 minutes, 40 cycles of 
amplification with denaturation at 95°C for 30 seconds, annealing at 55°C for 1 
minute and elongation at 72°C for 1 minute. Data was collected at the elongation 
phase. A melt curve was performed by cooling to 55°C for 1 minute, then 
increasing the temperature to 95°C. Gene expression was normalized to GAPDH. 
2.13 Real Time PCR for Sorted Cells 
2.13.1 Quantifying minute amounts of RNA 
mRNA extracted from sorted T2 MZP and MZ B cells were quantified using 
Quant-iT™ RiboGreen®RNA Reagent and Kit (Invitrogen) according to the 
manufacturer’s instructions. The low range assay was performed. Briefly, 100µl 
of 2000x diluted Quant-iT Ribogreen working reagent solution was added to 
100µl of diluted sample in an opaque 96-well flat bottom plate. The plate was left 
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to incubate in the dark for 2-5 mins at room temperature. A spectrofluorometer 
was used to measure the fluorescence at an excitation wavelength of 480nm and 
an emission wavelength of 520nm. Amount of RNA was determined by 
comparison against a low-range standard curve. 
2.13.2 cDNA synthesis and RNA amplification for sorted B cells 
15µg of total RNA from sorted cells was amplified and used for cDNA synthesis 
using MessageBOOSTER™ Whole Transcriptome cDNA Synthesis Kit for qPCR 
according to the manufacturer’s instructions. The following steps were performed. 
1) Round 1 First Strand cDNA synthesis: RNA sample was reverse-transcribed 
into first-strand cDNA. The reverse transcription reaction was primed using 
primers consisting off oligo(dT) and a population of mixed sequence primers each 
containing a bacteriophage T7 RNA polymerase promoter at the 5’ end. Reverse 
transcriptase was performed using the MMLV Reverse Transcriptase provided in 
the kit. 
2) Round 1, Second Strand cDNA synthesis: Second strand cDNA synthesis was 
performed to generate double-stranded DNA (dsDNA) containing a T7 
transcription promoter in an orientation that will generate antisense RNA (aRNA) 
during subsequent in vitro transcription reaction. 
3) Round 1, In Vitro Transcription: High yields of aRNA were produced in a 
rapid in vitro transcription reaction that uses the dsDNA produced in Step 2. 
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4) Round 1, RNA Purification: The aRNA produced was purified by spin-column 
chromatography. 
5) Round 2, cDNA synthesis: The purified aRNA was reverse-transcribed into 
first strand cDNA using MMLV Reverse Transcriptase. The reaction was primed 
using random sequence hexamer primers, resulting in the production of a sense-
strand cDNA that could be used for RT-qPCR using sybr green dye. 
2.13.3 Quantification of sorted cells gene expression by RT-PCR 
Real-time polymerase chain reactions (RT-PCR) were performed in triplicates on 
a 7500 Real-Time PCR System (Applied Biosystems). Each RT-PCR contained 
10µl of iTaq SYBR Green supermix with ROX (Biorad), 250nM forward and 
reverse primers, 7µl of RNase free water and 1µl of cDNA template (diluted 4 
times from stock). The cycling conditions for all genes were: denaturation at 95°C 
for 10 minutes, 40 cycles of amplification with annealing and extension at 60°C 
for 30 seconds. Data was collected at the elongation phase. A melt curve was 
performed by cooling to 55°C for 1 minute, then increasing the temperature to 
95°C. Gene expression was normalized to GAPDH. 
2.14 Culture of splenocytes for quantification of apoptotic MZ B cells 
1x106 splenocytes were seeded in 96 round bottom plates and cultured at 37°C in 
complete RPMI-1640 medium (Sigma) for 6 hours.  
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2.15 Annexin V and PI viability assay 
MZ B cells were FACS stained for surface markers. The cells were washed once 
with cold 1xPBS  and resuspended in 100µl of Annexin V Binding Buffer at a 
concentration of 1x106 cells/ml. 2µl of Annexin V and 1µl of PI was added into 
each tube and incubated for 15 minutes at room temperature in the dark. After 
incubation, 200µl of Annexin V binding buffer was added to each tube. Cells 
were analyzed by flow cytometry immediately. 
2.16 Proliferation Assays 
2.16.1 In vivo labeling of mouse cells with 5-bromo-2'-deoxyuridine (BrdU) 
In vivo labeling of mouse cells was performed using BD PharmingenTM BrdU 
Flow Kit (BD Biosiences) according to the manufacturer’s instructions. Mice 
were fed with drinking water supplemented with BrdU at a concentration of 
0.8mg/ml for a period of 5 weeks. The BrdU mixture was changed once every 2 
days. 
 
2.16.2 Intracellular staining of BrdU+ cells for flow cytometric analysis of 
splenic B cells proliferation 
Mice were pulsed with BrdU as described above. Surface antigen staining of B 
cell subsets was performed prior to staining of intracellular BrdU with the BD 
PharmingenTM BrdU Flow Kit. Cells were fixed with 100µl of BD 
Cytofix/Cytoperm Buffer for 15 mintues at room temperature and washed with 1x 
BD Perm/Wash Buffer. To permeabilize the cells, 100µl of BD Cytoperm 
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Permeabilization Buffer Plus was added to the cells and incubated for 10 minutes 
on ice. After incubation, cells were washed with 1x BD Perm/Wash Buffer. Re-
fixation of the cells was performed by resuspending cells in 100µl of BD 
Cytofix/Cytoperm Buffer and incubated for 5 minutes at room temperature. After 
washing with 1x BD Perm/Wash Buffer, cells were treated with 100µl of DNase 
diluted to 300µg/ml in PBS and incubated for 1 hour at 37°C to expose 
incorporated BrdU. Cells were washed with 1x BD Perm/Wash Buffer. 
Intracellular staining of BrdU was performed by resuspending the cells in 50µl of 
BD Perm/Wash Buffer containing diluted APC conjugated anti-BrdU antibodies 
and incubated for 20 minutes at room temperature. Cells were washed with 1x BD 
Perm/Wash Buffer and resuspended in FACS staining buffer for flow cytometric 
analysis. 
 
2.16.3 MUH Proliferation Assay 
Sorted MZ B cells were cultured in complete RPMI (Sigma) supplemented with 
10%FCS, penicillin-streptomycin and L-glutamate overnight in 96-well round 
bottom plates. After incubation, cells were washed with 1xPBS to remove any 
traces of FCS. 10,000 cells were seeded into opaque 96-well flat bottom plates 
and incubated with 100µg of 4-methylumbelliferone (MUH) working solution for 
30 mins at 37°C. Fluorescence was determined by a M2 spectrophotometer 
(Molecular Devices) with an excitation wavelength set at 355nm and emission 
wavelength set at 480nm. 
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2.17 Uptake of dil-oxLDL by MZ B cells and FO B cells 
40µg of dil-oxLDL (Biomedical Technologies) was intravenously injected into 
the mice. After 1 hour, the mice were sacrificed and the spleen was collected for 
isolation of splenocytes. Surface antigen staining of MZ B cells and FO B cells 
was performed. The uptake of dil-oxLDL by MZ B cells and FO B cells was 
assessed by flow cytometry.  
2.18 Anti CD1d blocking antibody treatment 
500µg of α-CD1d blocking antibody (19G11) (BioXcell) was injected 
intraperitoneally into mice once every 3 days for a duration of 5 weeks. After 5 
weeks, the spleen was harvested and cell suspensions were prepared for FACS 
staining of surface markers. 
2.19 Activation of iNKT cells by aGalCer injection 
8-10 weeks mice were injected with 1µg of αGalCer in 200µl of 1xPBS 
intraperitoneally. Mice were bled 4 hours after injection and the cytokines IL-4 
and IFN-γ were measured in the serum. 3 days later, the mice were sacrificed, 
spleens were harvested, and single cell suspensions were prepared. 
2.20 Induction of iNKT cell anergy 
Mice were injected with 5µg of αGalCer (Enzo) in 200µl of 1xPBS 
intraperitoneally. One month later, mice were reinjected with 1µg of αGalCer. 
Mice were bled 4 hours after reinjection of αGalCer and the cytokines IL-4 and 
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IFN-γ were measured in the serum. 3 days after reinjection, the mice were 
sacrificed, spleens were harvested, and single cell suspensions were prepared. 
2.22 Statistical analysis 
Statistical analysis was performed using unpaired, two tailed t-test for comparison 
between 2 groups. Comparisons of 3 or more groups were performed using the 
Mann-Whitney test. All the data are presented as means ± SD. Prism 5 software 
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Introduction 
 In recent years, studies have begun to unravel a role for splenic B 
lymphocytes in atherosclerosis. Recent findings provide evidence that the effects 
of B cells on atherosclerotic disease progression may be subset dependent, with 
B1a cells being protective while conventional B-2 cells being pathogenic. 
However, within the splenic B-2 cell compartment, other populations of B cells 
with different phenotypes exist, indicating that the various subsets may impact 
atherosclerosis in different ways. This chapter will focus on characterizing the 
different B cell subpopulations in the spleen of apoE-/- mice during the 
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Results 
3.1 apoE-/- mice develop hypercholesterolemia 
apoE-/- mice fed a standard chow diet develop minimal cholesterolemia, 
and their plasma cholesterol reached an average of 500 mg/dl at 6 weeks of age. 
In contrast, WT mice which were age, sex and diet-matched had cholesterol levels 
lower than 100 mg/dl (Fig. 3.1). At 20 weeks of age, cholesterol levels in apoE-/- 
mice increased significantly, reaching an average of 2000 mg/dl whereas the WT 
levels remained unchanged (Fig.3.1). This is consistent with previous studies 
(Plump, Smith et al. 1992, Nakashima, Plump et al. 1994, Reddick, Zhang et al. 
1994) showing that a high-cholesterol, high-fat (HF) diet accelerates and 
exacerbates plasma cholesterol in apoE-/- mice. As a consequence of 
hypercholesterolemia, apoE-/- mice at 20 weeks of age fed a HF diet develop 
atherosclerotic lesions in contrast to WT mice (Fig. 3.2). 
 
  
Figure 3.1 Total cholesterol in 6 week and 20 week old WT and apoE-/- mice. 
Data are represented as mean ± SD for each group. Significant differences are 
designated by *** where p<0.0001. 
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Figure 3.2 Oil red O staining of lipids in the aorta. (A) 20 week old WT on HF 
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3.2 Hypercholesterolemia does not affect spleen size and cellularity in 
atherosclerotic apoE-/- mice 
 The spleen is the major lymphoid organ consisting of diverse B cell 
subpopulations. It is capable of mounting immune responses against blood borne 
antigens such as oxLDL, making it a potential target for atherosclerosis studies. 
To examine whether hypercholesterolemia affects the physical and cellular 
properties of the spleen, we measured the size and quantified the total cell number 
of spleens from 24 week old WT and apoE-/- mice fed a HF diet. We did not 
observe any significant differences in spleen size and cell number between 24 
week old WT and apoE-/- mice, suggesting that hypercholesterolemia does not 















Figure 3.3 Spleen size and cellularity in 24 week old WT and apoE-/- mice. A) 
Representative image of a spleen from WT and apoE-/- mice. B) Spleen cellularity 
of WT and apoE-/- mice. Results are representative of 2 experiments (n=7). 





	   58	  
3.3 Expansion of MZ B cells in atherosclerotic apoE-/- mice 
To investigate the possible involvement of B cell subpopulations in the 
initiation and progression of atherosclerosis, we quantified the percentages of MZ 
and FO B cells in the spleens of 6 week old apoE-/- mice that had yet to develop 
the disease and 20 week old apoE-/- mice fed a chow or HF diet that exhibit 
marked atherosclerotic lesions. Using flow cytometry, MZ B cells were identified 
as B220+CD21highCD23low and FO B cells were identified as 
B220+CD23intCD21low/int (Fig. 3.4 A). There were no significant differences in the 
percentages of MZ B cells and FO B cells between WT and apoE-/- mice at 6 
weeks of age (Fig. 3.4 B, C), suggesting that the deficiency in apoE does not 
affect the early development of B cell subsets in the spleen. In contrast, the 
percentage of MZ B cells significantly increased by two fold in 20 and 60 week 
old apoE-/- mice fed a HF and chow diet respectively compared to 6 week old 
apoE-/- mice (Fig.3.4 B,C). In addition, a two fold increase in the number of MZ B 
cells was also observed in 20 week old apoE-/- mice fed a HF diet (Fig. 3.4 D). 
Immunohistological analysis of the spleens further confirmed the expansion of 
MZ B cells in atherosclerotic apoE-/- mice, as shown by an enlarged region of 
CD1d-bright cells which colocalize with Moma-1+ metallophilic macrophages 
that surround the B cell follicles (Fig. 3.5). This expansion of MZ B cells in 20 
and 60 week old apoE-/- mice was also accompanied by a significant decrease in 
the FOB cell percentage and number compared to their respective WT 
counterparts (Fig. 3.4 B,C, E). These results suggest that hypercholesterolemia in 
apoE-/- mice was associated with an increase in the percentage and number of MZ 
B cells and a decrease in the percentage and number of FO B cells. 
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Figure 3.4 Flow cytometric evaluation of splenic MZ B cells and FO B cells. 
A) From B220+ cells, FO B cells were gated as the CD23int CD21low/int population. 
MZ B cells were gated as the CD21high CD23low population. B) Percentage of MZ 
B cells between apoE-/- and WT mice C) Percentage of FO B cells between apoE-
/- and WT mice. D) Number of MZ B cells in 20 weeks between apoE-/- and WT 
mice E) Number of FO B cells in 20 weeks between apoE-/- and WT mice. Results 
are representative of 3 experiments (n=5). Significant differences were designated 
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Figure 3.5 Immunohistological analysis of MZ B cells. Immunofluorescence 
staining of MZ B cells (CD1d+) and metallophilic macrophages (Moma-1+) in the 
spleen (100x magnification).  
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Summary 
 In this chapter, we characterized the percentages of B cell subpopulations 
in the spleens of atherosclerotic apoE-/- mice. Hypercholesterolemia in apoE-/- 
mice was associated with a 2 fold increase in the percentage of MZ B cells. This 
expansion of MZ B cells was only observed during advanced stages of the disease 
(> 20 weeks old). In addition, the enlargement of the MZ B cell compartment was 
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Introduction 
 Elevated plasma cholesterol is a known risk factor for the development 
of coronary heart disease. Ezetimibe is a novel cholesterol absorption inhibitor 
that blocks the intestinal absorption of dietary and biliary cholesterol (Bays, 
Neff et al. 2008). Ezetimibe exerts its effect by blocking intestinal sterol 
transporters known as Niemann-Pick C1 like proteins. This reduces the 
amount of cholesterol delivered to the liver, resulting in a compensatory 
upregulation of hepatic LDL receptors, enhancing clearance and lowering 
plasma LDL levels (Repa, Turley et al. 2005). Results from pre-clinical 
studies in human and animal models have shown that ezetimibe monotherapy 
or in combination with statin therapy lowers LDL cholesterol levels (Sudhop, 
Lutjohann et al. 2002, Bays and Stein 2003). In apoE-/- mice, ezetimibe 
reduced serum cholesterol levels by more than 50% and resulted in decreased 
aortic lesions (Nutescu and Shapiro 2003).   
In this chapter, we will discuss the effect of cholesterol lowering and 
atherosclerosis regression on MZ B cells expansion in apoE-/- mice.  
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Results 
4.1 Ezetimibe lowers total plasma cholesterol levels in atherosclerotic 
apoE-/- mice 
 Since we found an expansion of MZ B cells in apoE-/- mice during 
disease progression, we next investigated whether the expansion of MZ B 
cells could be affected when we induced disease regression. To address this 
question, 12 week old apoE-/- mice were treated with ezetimibe by oral gavage 
for 3 months. The serum was collected at weeks 4, 9 and 12 to monitor the 
cholesterol levels throughout the treatment process (Fig. 4.1 A). Prior to 
ezetimibe treatment (Week 0), apoE-/- mice at 12 weeks of age exhibited 
marked hypercholesterolemia with total cholesterol levels reaching 2000mg/dl 
(Fig. 4.1 B). By 4 weeks of treatment, ezetimibe significantly reduced total 
cholesterol levels in apoE-/- mice, which reached 500 mg/dl after 12 weeks of 
treatment (Fig. 4.1 B). In contrast, plasma cholesterol levels in apoE-/- mice 
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Figure 4.1 Total plasma cholesterol upon Ezetimibe treatment at week 0, 
4, 9 and 12. A) Diagram illustrates the drug treatment used to lower plasma 
cholesterol levels in apoE-/- mice. B) Mice fed a HF diet were 12 weeks at the 
beginning of the treatment with ezetimbe (Week 0). Cholesterol levels were 
measured at 4 weeks, 9 weeks and 12 weeks during the treatment period. 
Results are pooled from 3 experiments with 5-6 mice per group from each 
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4.2 Treatment with cholesterol lowering drug Ezetimibe decreases the 
percentage of MZ B cells in apoE-/- mice 
 At the end of the 12 weeks ezetimibe drug treatment procedure, the 
mice were euthanized and the spleen was collected for immunohistological 
analysis of MZ B cells and quantification of the percentages of MZ B cells 
and FO B cells by flow cytometry (Fig. 4.1 A). Results showed that the 
reduction of cholesterol levels in atherosclerotic apoE-/- mice restored the 
percentage of MZ B cells to WT levels (Fig. 4.2 A). This was also confirmed 
by immunofluorescence staining as shown by a significant reduction in the 
amount of CD1d bright-cells surrounding the ring of Moma-1+ macrophages 
demarcating the MZ (Fig. 4.3). In addition, the percentages of FO B cells in 
treated apoE-/- mice increased to reach WT levels. (Fig. 4.2 B). These results 
provide evidence that hypercholesterolemia accounts for the expansion of MZ 












Figure 4.2 Flow cytometric analysis of MZ B cells and FO B cells in 
Ezetimibe treated mice. A) Percentage of MZ B cells B) Percentage of FO B 
cells. Results are an average of 2 experiments (n=8). Significant differences 
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Figure 4.3 Immunohistological analysis of MZ B cells. 
Immunofluorescence staining of MZ B cells (CD1d+) and metallophilic 
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Summary 
 We described in this chapter that inducing atherosclerosis regression 
by lowering plasma cholesterol levels through Ezetimibe drug treatment 
reversed the expansion of MZ B cells and increased the percentage of FO B 
cells to reach WT levels. Taken together, these results suggest that altering 
cholesterol in apoE-/- mice affects the percentage of B cell subpopulations in 

















































	   71	  
Introduction 
 Autoimmune diseases are often associated with chronic inflammation and 
immune dysregulation, which may lead to dyslipidemia, vascular dysfunction, 
atherosclerotic lesions and autoantibody production (Shoenfeld, Gerli et al. 2005, 
Nussinovitch and Shoenfeld 2011, Artenjak, Lakota et al. 2012). These symptoms 
are often manifested in atherosclerotic disease. Thus, atherosclerosis is described 
to be an autoimmune disease. B lymphocytes have been implicated as contributors 
to autoimmunity. The ability of MZ B cells to respond to innate signals, generate 
antigen-specific antibody responses and present antigen to T cells allows them to 
be potential players in the development of autoimmune diseases. CD1d 
expressing MZ B cells may interact with CD1d restricted iNKT cells, which in 
turn provide help for lipid specific antibody responses. Autoantibodies produced 
by B cells are not only used as diagnostic markers for autoimmunity but also 
contribute significantly to disease pathogenesis. Autoantibodies against oxLDL 
have been associated with atherosclerosis, with elevated anti-oxLDL antibodies 
found in atherosclerotic lesions and in patients with atherosclerosis (Salonen, Yla-
Herttuala et al. 1992). This chapter will focus on the potential functions of MZ B 






	   72	  
5.1 MZ B cells may internalize dil-oxLDL 
 Antigen internalization is required for mounting a specific immune 
response. To investigate whether lipid antigens such as oxLDL could be 
internalized by MZ B cells, 40µg of dil-oxLDL was intravenously injected into 
WT mice and internlization by MZ B cells and FO B cells was assessed using 
flow cytometry after an hour. We found that MZ B cells, but not FO B cells were 
able to internalize dil-oxLDL at this time (Fig. 5.1), suggesting that MZ B cells 
may be capable of responding to oxLDL directly. 
 














MZ B cells FO B cells 
None 
dil-oxldl mouse 1 
dil-oxldl mouse 2 
dil-­‐oxLDL	  mouse	  1 
dil-­‐oxLDL	  mouse	  2 
None 
dil-oxLDL 
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5.2 Expansion of MZ B cells is associated with an increase in total IgM and 
LDL/oxLDL IgM antibody production in cultured splenocytes 
 Having shown that MZ B cells are able to internalize oxLDL and that they 
are known to be one of the major producers of natural IgM antibodies, we 
hypothesized that MZ B cells are involved in the production of IgM and 
LDL/oxLDL specific IgM antibodies in apoE-/- mice. As a first approach, 
splenocytes isolated from 20 week old WT and apoE-/- mice fed a HF diet were 
cultured in 10% FCS for 2 days. The supernatant was collected and the total IgM 
and LDL/oxLDL specific IgM titre was quantified by ELISA (Fig. 5.2 A). We 
found a 2 fold increase in total IgM produced by apoE-/- splenocytes compared to 
WT splenocytes after 2 days in culture (Fig. 5.2 B). Compared to cultured WT 
splenocytes, we detected elevated levels of LDL and oxLDL specific IgM 
antibodies produced by cultured apoE-/- splenocytes (Fig. 5.2 C, D). These results 
suggest that the expansion of MZ B cells in apoE-/- mice was associated with 
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Figure 5.2 Analysis of Total IgM and LDL/oxLDL specific IgM antibodies in 
cultured splenocytes from 20 week old WT and apoE-/- mice. A) Experimental 
outline depicting the culturing of splenocytes for analysis of IgM and lipid 
specific IgM antibodies by ELISA B) Total IgM in cultured splenocytes C) LDL 
IgM in cultured splenocytes D) oxLDL IgM in cultured splenocytes. Data is 
representative of 2 independent experiments (n=4). Significant differences were 
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5.3 Sorted apoE-/- MZ B cells produce more IgM antibodies than WT MZ B 
cells  
 To directly determine whether MZ B cells in apoE-/- mice produce more 
IgM antibodies compared to WT mice, we selectively sorted MZ B cells from 24 
week old WT and apoE-/- mice and cultured them in 10% FCS for 2 days. The 
total IgM antibody produced was quantified by ELISA (Fig. 5.3 A). We found a 
slight increase in total IgM produced by apoE-/- MZ B cells compared to WT MZ 
B cells (Fig. 5.3 B).  
 To confirm these findings, we cultured 800,000 MZ B cells selectively 
sorted from 24 week old WT and apoE-/- mice and quantified the number of IgM 
producing MZ B cells after 1 day by Elispot (Fig. 5.4 A). We observed a 2 fold 
increase in the number of spots produced by apoE-/- MZ B cells compared to WT 
MZ B cells (Fig. 5.4 B), suggesting that there were more IgM producing MZ B 
cells in apoE-/- mice compared to WT mice. In addition, larger spots were 
produced by apoE-/- MZ B cells compared to WT MZ B cells (Fig. 5.4 C), 
suggesting that apoE-/- MZ B cells produce more IgM antibodies compared to WT 











Figure 5.3 Analysis of Total IgM in cultured MZ B cells sorted from 24 week 
old WT and apoE-/- mice. A) Experimental outline depicting the culturing of MZ 
B cells for analysis of Total IgM antibodies by ELISA B) Total IgM produced by 
sorted MZ B cells in culture. Data is representative of 2 independent experiments 
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Figure 5.4 Analysis of Total IgM in cultured MZ B cells sorted from 24 week 
old WT and apoE-/- mice. A) Experimental outline depicting the culturing of MZ 
B cells for analysis of Total IgM antibodies by Elispot B) Number of IgM 
producing MZ B cells C) Photograph of Elispot plate seeded with WT and apoE-/-  
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Summary 
 Taken together, these results suggest that the expansion of MZ B cells was 
associated with an increase in the total IgM and LDL/oxLDL specific antibodies 
in cultured apoE-/- splenocytes compared to cultured WT spenocytes. In addition, 
sorted apoE-/- MZ B cells produced an increased amount of total IgM antibodies 























Chapter 6  
Mechanisms underlying MZ B cell expansion in 
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Introduction 
In the previous chapters, we have shown that hypercholesterolemia was 
associated with a 2 fold increase of the MZ B cell pool in atherosclerotic apoE-/- 
mice. We also provided evidence that the expansion of MZ B cells may be 
reversed by decreasing cholesterol levels in diseased apoE-/- mice.  
In this chapter, we will explore the possible mechanisms driving MZ B cells 
expansion in apoE-/- mice. The list of mechanisms that we will discuss is as 
follows: 
The expansion of MZ B cells in apoE-/- mice could be due to: 
1) Altered development of MZ B cells  
2) Increased activation status and proliferative capacity of MZ B cells 
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6.1.1 Expansion of splenic Marginal Zone B Cells in atherosclerotic apoE-/- 
mice is not related to an increase in Transitional B cell populations  
 Upon arrival in the spleen, naive immature B cells that survive negative 
selection pass through transitional stages T1 and T2 and these transitional B cells 
are named Transitional 1 (T1) and Transitional 2 Marginal Zone Precursor (T2 
MZP) cells (Shapiro-Shelef and Calame 2005). MZ B cells and FO B cells 
develop from a common T2 MZP cell during B cell development (Allman, 
Srivastava et al. 2004). If the B cell developmental pathway was skewed to favor 
the differentiation of MZ B cells instead of FO B cells in atherosclerotic apoE-/- 
mice, we will expect more T2 MZP cells to develop into MZ B cells and a 
corresponding decrease in the FO B cell compartment.  
 To investigate whether the expansion of MZ B cells was due to an 
increase in the transitional precursor cell populations, the percentages of T1 and 
T2 MZP cells in 16 and 24 week old WT and apoE-/- mice were quantified by 
flow cytometry. T1 B cells were identified as the B220high CD23neg IgM+ CD21low 
population while T2 MZP cells were identified as the B220high CD23high IgMhigh 
CD21high population (Fig. 6.1 A). Compared to WT mice, we did not detect any 
difference in the percentages of T1 and T2 MZP cells in apoE-/- mice at both 16 
and 24 weeks of age (Fig. 6.1 B, C), suggesting that the expansion of MZ B cells 
was unlikely to be related to an increase in the percentage of transitional precursor 
B cells. 
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Figure 6.1 Flow cytometric evaluation of T1 and T2 MZP B cells in the 
spleen. A) T1 B cells were identified as the B220high CD23neg CD21low IgM+ 
population while T2 MZP cells were identified as the B220high CD23high CD21high 
IgMhigh population. B) Percentages of T1 B cells between 16 and 24 week old WT 
and apoE-/- mice C) Percentages of T2 MZP cells between 16 and 24 week old 
WT and apoE-/- mice. Results are representative of 3 experiments (n=4). Error 
bars represent SD. 
B 
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6.1.2 Expansion of MZ B cells in apoE-/- mice is not associated with changes 
related to Notch2-DL1 signaling  
 Although we did not see any changes in the percentages of transitional 
precursor B cell subpopulations, other factors that could skew the developmental 
pathway towards the MZ B cell fate may contribute to their expansion in apoE-/- 
mice. The Notch 2-DL1 signalling is critical for the generation of MZ B cells at 
the branching point of MZ B and FO B cells in the spleen. To investigate whether 
increased Notch 2 receptor expression contributes to MZ B cells expansion in 
apoE-/- mice, we selectively sorted T1 B cells, T2 MZP cells and MZ B cells from 
24 week old WT and apoE-/- mice fed a HF diet and the mRNA expression of 
Notch 2 was quantified by Real Time-Polymerase Chain Reaction (RT-PCR). We 
did not find any significant difference in the mRNA expression of Notch 2 
between WT and apoE-/- T1, T2 MZP and MZ B cells sorted from 24 week old 
mice (Fig. 6.2 A). To determine whether increased DL1 ligand availability in the 
spleen could account for MZ B cells expansion in apoE-/- mice, we quantified the 
mRNA level of DL1 in the spleen of 24 week old WT and apoE-/- mice. We did 
not find any significant differences in the mRNA expression of DL1 in the spleen 
of 24 week WT and apoE-/- mice (Fig. 6.2 C). We went on to investigate whether 
there were changes at the level of Notch signaling suppressor by quantifying the 
mRNA levels of MINT in WT and apoE-/- T1, T2 MZP and MZ B cells sorted 
from 24 week old mice. We did not find any significant difference in the 
expression of MINT mRNA between sorted WT and apoE-/- T1, T2 and MZ B 
cells (Fig. 6.2 B). Taken together, these results suggest that the expansion of MZ 
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B cells in apoE-/- mice was not associated with increased Notch 2-DL1 signaling 
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Figure 6.2 mRNA quantification of developmental factors associated with 
Notch 2 signaling in sorted T1, T2 MZP and MZ B cells. A) Notch 2 mRNA 
expression in sorted cells isolated from 24 week old WT and apoE-/- mice B) 
MINT mRNA expression in sorted cells isolated from 24 week old WT and apoE-
/- mice C) DL1 mRNA expression in 24 week old WT and apoE-/- mice spleen. 
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6.1.3 Expansion of MZ B cells in apoE-/- mice is not associated with 
alterations in the levels of helix loop helix transcription factors  
 Other than Notch 2-DL1 signalling, other factors such as the helix loop 
helix proteins could also be involved in regulating the MZ B/ FO B cell fate. 
When the transcription factor E2A is in high abundance, FO B cell development 
is favored. ID2 and ID3 are proteins that oppose E2A activity and the expression 
of these ID proteins favors the development of MZ B cells rather than FO B cells 
(Murre 2005). Therefore, a decrease in E2A and/or an increase in ID2/ID3 levels 
would promote MZ B cell development at the expense of FO B cells.  
 To determine whether changes in the levels of helix loop helix proteins 
contribute to the expansion of the MZ B cell compartment in atherosclerotic apoE-
/- mice, we selectively sorted T2 MZP cells and MZ B cells from 24 week old WT 
and apoE-/- mice fed a HF diet and the mRNA expression of E2A, ID2 and ID3 
was quantified by RT-PCR. We did not observe any significant differences in the 
mRNA levels of E2A, ID2 and ID3 between sorted WT and apoE-/- T2 MZP and 
MZ B cells (Fig. 6.2 A-C). These results suggest that the expansion of MZ B cells 
was not related to alterations in the levels of helix loop helix proteins, which are 









Figure 6.3 mRNA quantification of developmental factors that regulate 
Notch 2 signaling in sorted T2 MZP and MZ B cells from 24 week old WT 
and apoE-/- mice fed a HF diet. A) E2a mRNA expression B) Id2 mRNA 
expression C) Id3 mRNA expression. Data is an average representation of 2 
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6.1.4 Expansion of MZ B cells in apoE-/- mice is not associated with a 
deficiency in Fli-1 and its downstream factors 
 Friend leukemia integration 1 transcription factor (Fli-1) is a member of 
the Ets family expressed in haematopoetic cells. It is reported that mice deficient 
for Fli-1 demonstrated an increase in MZ B cells and a decrease in FO B cells, 
suggesting that Fli-1 is a negative regulator for MZ B cell development and a 
positive regulator for FO B cell development (Zhang, Moussa et al. 2008). Fli-1 
deficiency leads to reduced binding to its promoter mb-1, which controls the 
expression of Igα (CD79a) that constitutes the BCR (Zhang, Moussa et al. 2008). 
This results in weak BCR signaling which favors an increase in MZ B cells and a 
decrease in FO B cells. In addition, Fli-1 regulates the expression of BCL-2 
(Pereira, Quang et al. 1999, Lesault, Quang et al. 2002). Mice that overexpress 
BCL-2 lack MZ B cells while BCL-2 knockout mice have an increased number of 
MZ B cells (Brunner, Marinkovic et al. 2003). Therefore, a reduction in Fli-1 
would result in decreased expression of BCL-2, which could contribute to an 
increase in the number of MZ B cells.  
 To investigate whether the expansion of MZ B cells in atherosclerotic 
apoE-/- mice was due to Fli-1 deficiency and/or its downstream effects, we 
quantified the mRNA expression of Fli-1, CD79a, mb-1 and BCL-2 in T2 MZP 
and MZ B cells selectively sorted from 24 week old WT and apoE-/- mice by RT-
PCR. Results showed that there was no significant differences in the mRNA 
expression of Fli-1, CD79a, mb-1 and BCL-2 between WT and apoE-/- T2 MZP 
and MZ B cells (Fig. 6.4 A-D). Taken together, these results indicate that the 
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expansion of MZ B cells in diseased apoE-/- mice was not due to a deficiency in 





























Figure 6.4 mRNA expression of other developmental factors that favors MZ 
B cell development in sorted T2 MZP and MZ B cells from 24 week old WT 
and apoE-/- mice fed a HF diet. A) Fli-1 mRNA expression B) CD79a mRNA 
expression C) mb-1 mRNA expression D) BCL-2 mRNA expression. Data is an 
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Summary 
 The enlargement of the MZ B cell compartment was not due to an increase 
in the percentage of the transitional precursor cell populations. We also showed 
that the expansion of MZ B cells was not associated with alterations in their 
development regulated by Notch 2-DL1 signaling, helix loop helix factors as well 
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6.2.1 Expansion of splenic Marginal Zone B cells in apoE-/- mice is not 
associated with their increased activation and expression of co-stimulatory 
molecules  
 B cells are activated by antigen binding to the B cell receptor. The early 
cellular events that are induced by antigen-mediated cross linking of the B cell 
receptor prepare the B cell for subsequent proliferation and differentiation. This 
includes increased expression of co-stimulatory molecules CD40, CD80 and 
CD86 as well as upregulation of activation marker CD69 on B cells. We 
hypothesized whether the expansion of MZ B cells in apoE-/- mice could be 
attributed to an increase in their activation state, which leads to their proliferation. 
 First, we sought to examine the activation status of MZ B cells in 24 week 
old WT and apoE-/- mice fed a HF diet by analyzing the expression levels of co-
stimulatory molecules and of the activation marker CD69 through flow cytometry. 
We did not find any significant differences in the expression of co-stimulatory 
molecules CD40, CD80 and CD86 on MZ B cells between 24 week old WT and 
apoE-/- mice (Fig. 6.5). We also failed to detect any upregulation of CD69 on MZ 
B cells in 24 week old apoE-/- mice compared to their matching WT counterparts 
(Fig. 6.5). These results suggest that the expansion of MZ B cells in apoE-/- mice 
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Figure 6.5 Flow cytometric examination of co-stimulatory molecules and 
activation marker CD69 expression on MZ B cells. Expression of co-
stimulatory molecules (CD40, CD80 and CD86) and activation marker CD69 on 
MZ B cells in 24 week old WT and apoE-/- mice fed a HF diet. Data is an average 
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6.2.2 The expansion of MZ B cells in apoE-/- mice is independent of CD1d and 
iNKT cell function 
 MZ B cells express high levels of CD1d which function to present lipid 
antigens to CD1d restricted iNKT cells. CD1d is a non classical MHC Class I like 
molecule that is involved in lipid antigen presentation. Recognition of CD1d on 
MZ B cells by iNKT cells, plus the engagement of co-stimulatory molecules 
CD40, CD80 and CD86 are important for cognate iNKT cell help to MZ B cell 
proliferation responses to lipid antigens such as α-GalCer. This was supported by 
studies showing that CD1d+/+ B cells but not CD1d-/- B cells proliferate when co 
cultured with iNKT cells in the presence of either αGalCer or NP-αGalCer 
(Leadbetter, Brigl et al. 2008). It was also reported that iNKT cells preferentially 
stimulate greater proliferation of MZ B cells than FO B cells in the presence of 
NP-αGalCer (Leadbetter, Brigl et al. 2008). Thus, we hypothesized whether iNKT 
cells could be involved in MZ B cell proliferation in apoE-/- mice.  
 First, we asked if the expansion in the MZ B cell compartment could be 
attributed to increased antigen presentation via CD1d, resulting in increased iNKT 
cell help for MZ B cells proliferation. To test this, we examined the expression of 
CD1d on MZ B cells in 24 week old WT and apoE-/- mice by flow cytometry. We 
did not observe any differences in the expression of CD1d on MZ B cells between 
WT and apoE-/- mice, suggesting that the expansion of MZ B cells was not 
associated with increased lipid antigen presentation via CD1d (Fig. 6.6).  
	   98	  
 To determine whether the percentage of iNKT cells change with 
atherosclerosis progression, we quantified the percentage of iNKT cells in the 
spleen of 24 week old WT and apoE-/- mice by flow cytometry. We did not find 
any significant difference in the percentage of iNKT cells between 24 week old 
WT and apoE-/- mice fed a HF diet (Fig. 6.7).  
 Next, we went on to investigate whether iNKT cells were required for the 
proliferation of MZ B cells in apoE-/- mice by blocking the interaction of MZ B 
cells and iNKT cells through intraperitoneal administration of a CD1d blocking 
antibody (19G11) into atherosclerotic apoE-/- mice twice a week for 5 weeks (Fig. 
6.8 A). To detect proliferating cells, mice were fed with BrdU supplemented 
drinking water from the 2nd week until the end of week 5. BrdU is a synthetic 
thymidine analog that gets incorporated into a cell’s DNA when the cell is 
dividing. Proliferating cells will be positive for BrdU. Using flow cytometry, we 
quantified the percentages of MZ B cells and FO B cells in the spleen. We did not 
find any significant difference in the percentages of MZ B cells and FO B cells 
between treated and untreated apoE-/- mice (Fig. 6.8 B, D). We went on to 
quantify the percentages of BrdU+ MZ B cells and BrdU+ FO B cells in the spleen. 
We did not find any significant difference in the percentages of proliferating MZ 
B cells and FO B cells between treated and non treated apoE-/- mice (Fig. 6.8 C, 
E). These results suggest that the expansion of MZ B cells in apoE-/- mice was not 
due to increased expression of CD1d and iNKT cells do not provide help for 
apoE-/- MZ B cells to proliferate in vivo. 
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Figure 6.6 Flow cytometric analysis of CD1d expression on MZ B cells in 24 
week old WT and apoE-/- mice fed a HF diet. Data is an average representation 
of 2 independent experiments (n=4). 
 
 
Figure 6.7 Flow cytometric analysis of splenic iNKT cells in 24 week old WT 
and apoE-/- mice fed a HF diet. Data is an average representation of 2 
independent experiments (n=4). Error bars represent SD. 
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Figure 6.8 Flow cytometric analysis of proliferating B cell subsets in CD1d 
blocking antibody treated mice. A) Schematic diagram showing the 
experimental protocol for blocking CD1d in atherosclerotic apoE-/- mice B,C) 
Percentage of MZ B cells and BrdU+ MZ B cells in the spleen D,E) Percentages 
of FOB cells and BrdU+ FOB cells in the spleen. Results are representative of 2 
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6.2.3 Expansion of MZ B Cells in apoE-/- mice was not associated with an 
increase in their intrinsic proliferative capacity  
 To confirm that MZ B cells in apoE-/- mice were not dividing, spleen 
sections from 24 week old WT and apoE-/- mice fed a HF diet were stained for 
Ki67, a cellular marker for proliferation. We did not detect any Ki67+ MZ B cells, 
suggesting that MZ B cells in apoE-/- mice were not proliferating (Fig 6.9). In 
addition, we sorted MZ B cells from 24 weeks old WT and apoE-/- mice fed a HF 
diet and their proliferation was measured using 4-methylumbelliferyl heptanoate 
(MUH) assay. MUH can be hydrolysed by intracellular esterases of viable cells 
resulting in the production of fluorescent 4-methylumbelliferone. The amount of 
fluorescence detected directly correlate with the cell’s metabolic activity and 
proliferation status. We did not find any difference in the absolute fluorescence 
unit between sorted WT and apoE-/- MZ B cells, suggesting that WT and apoE-/- 
MZ B cells have similar intrinsic proliferation capacity (Fig 6.10). Taken together, 
these results suggest that the expansion in the MZ B cell compartment was not 
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Figure 6.9 Immunohistological analysis of spleen sections stained for 
proliferation marker Ki67. A) Immunofluorescence staining of Ki67, MZ B 
cells (CD1d+) and metallophilic macrophages (Moma-1+) in the spleen (100x 
magnification). 
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Figure 6.10 Proliferation of sorted MZ B cells identified through MUH assay. 
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Summary 
 Taken together, our data suggests that the expansion of MZ B cells in 
apoE-/- mice was not related to an increase in their activation status as well as 
expression of co-stimulatory molecules (CD40, CD80, CD86).  We also showed 
that the expansion of the MZ B cell compartment was not due to increased lipid 
presentation via CD1d, and iNKT cells were not involved in providing help for 
MZ B cells proliferation. In addition, we also showed that MZ B cells from apoE-
/- mice did not proliferate, and therefore an increase in intrinsic proliferation does 
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6.3.1 Expansion of splenic MZ B Cells in atherosclerotic apoE-/- mice is not 
related to their increased survival via BAFF & BAFFR signaling 
Since macrophages and DCs produce BAFF, we hypothesized whether 
changes in the percentage of these cell types could contribute to elevated BAFF 
levels that promote the expansion of MZ B cells in atherosclerotic apoE-/- mice. 
Using flow cytometry, we quantified the percentage of splenic macrophages in 24 
week old WT and apoE-/- mice. Splenic RPMs were identified as the CD11blow, 
F4/80+ population (Fig. 6.11 A). We did not find any difference in the percentages 
of splenic RPMs between 24 week old WT and apoE-/- mice fed a HF diet (Fig. 
6.11 B). In addition, we also examined the activation status of RPMs through 
analyzing CD11b expression. We found that the expression of CD11b on RPMs 
was similar between 24 week old WT and apoE-/- mice, suggesting that they were 
equally activated (Fig. 6.11 A). Spleen sections from 24 week old WT and apoE-/- 
mice were stained for ERTR9 and Moma-1. MZM form an outer ring of 
macrophages surrounding the MZ and these cells were identified by expression of 
the C-type lectin ERTR9.  Metallophilic macrophages are located closer to the 
white pulp and form an inner ring of macrophages, and these cells were identified 
by the expression of Moma-1. Immunofluorescence staining of the spleens 
revealed that there were no differences in the amount and localization of MZM 
and metallophilic macrophages between 24 week old WT and apoE-/- mice (Fig. 
6.12- 6.13). Taken together, these results suggest that the expansion of MZ B cells 
in atherosclerotic apoE-/- mice was not associated with changes in the percentage, 
amount and localization of macrophage populations in the spleen. 
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 Mature DCs express CD11c and have moderate to high surface expression 
of MHC Class II. They can be further categorized into various subtypes based on 
their surface expression of CD8 and CD11b. Using flow cytometry, we quantified 
the percentage of total splenic conventional DCs in 24 week old WT and apoE-/- 
mice fed a HF diet. Total cDCs were gated as the CD11chigh MHC Class IIhigh 
population (Fig. 6.14 A). The cDCs were further gated into the CD11bhigh CD8- 
and CD11blow CD8+ subtypes (Fig. 6.14 A). Compared to WT mice, we found a 
significant increase in the total conventional DCs percentage in apoE-/- mice (Fig. 
6.14 B). This was confirmed by immunofluorescence staining of CD11c on spleen 
sections from 24 week old WT and apoE-/- mice. We observed a significant 
increase in CD11c bright DCs in the spleen of apoE-/- mice compared to WT mice. 
We did not find any differences in the proportion of both CD11bhigh CD8- and 
CD11blow CD8+ DC subtypes (Fig. 6.14 C, D). We also determined the activation 
of cDCs through examination of co-stimulatory molecule expression. We found 
that cDCs in 24 week old WT and apoE-/- mice expressed similar levels of CD80, 










Figure 6.11 Flow cytometric evaluation of splenic RPMs. A) RPMs were 
identified as the CD11blow F4/80+ population B) Expression of CD11b on RPMs 
C) Percentages of splenic RPMs. Results are representative of 2 experiments 
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Figure 6.12 Immunohistological analysis of MZ B cells and metallophilic 
macrophages. Immunofluorescence staining of MZ B cells (CD1d+) and 
metallophilic macrophages (Moma-1+) in the spleen (100x magnification). 
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Figure 6.13 Immunohistological analysis of MZ B cells and MZMs. 
Immunofluorescence staining of MZ B cells (CD1d+) and Marginal Zone 
Macrophages (ERTR9+) in the spleen (100x magnification).	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Figure 6.14 Flow cytometric analysis of dendritic cell subtypes in the spleen. 
A) Total conventional DCs was identified as the CD11c high MHC Class II high 
population. cDCs were further gated into CD11bhigh CD8- and CD11blow CD8+ 
subtypes. B) Total cDCs percentage C) Percentage of CD11b high CD8- cDCs D) 
Percentage of CD11b low CD8+ cDCs E) Expression of CD80, CD86 and CD40 on 
cDCs Results are pooled from 2 independent experiments with 4 mice per group 
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Figure 6.15 Immunohistological analysis of MZ B cells and DCs. 
Immunofluorescence staining of MZ B cells (CD1d+) and DCs (CD11c+) in the 
spleen (100x magnification).	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 Having found an increase in DCs that could potentially secrete BAFF, we 
went on to investigate whether the expansion of MZ B cells was associated with 
elevated levels of BAFF. We quantified the mRNA and protein levels of BAFF in 
the spleen and plasma by RT-PCR and ELISA. Results showed that there were no 
significant differences in the mRNA and protein levels of BAFF in the spleen and 
plasma of 24 week old WT and apoE-/- mice (Fig. 6.16). In addition, T2 MZP cells 
and MZ B cells in 16 and 24 week old WT and apoE-/- mice expressed similar 
levels of BAFFR (Fig. 6.17). Collectively, these results suggest that the expansion 
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Figure 6.16 Analysis of BAFF mRNA and protein levels in 24 week old WT 
and apoE-/- mice. A) BAFF mRNA in spleen B) BAFF protein in plasma C) 
BAFF protein in spleen. Results are representative of 2 experiments (n=4). Error 
bars represent SD. 
A 
B C 
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Figure 6.17 BAFFR expression by T2 MZP cells and MZ B cells from 16 and 
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6.3.2 Hypercholesterolemia is associated with decreased death of MZ B cells 
in apoE-/- mice  
 As we could not detect an increase in survival factors in apoE-/- mice, we 
proceeded to study the death of MZ B cells through measuring apoptosis. To 
address whether decreased death of MZ B cells could account for their expansion 
in atherosclerotic apoE-/- mice, splenocytes isolated from 24 week old WT and 
apoE-/- mice were cultured for 6 hours in the absence of stimuli to induce cell 
death. To identify dying cells, MZ B cells and FO B cells were stained for 
Annexin V and Propidium Iodide (PI) (Fig. 6.18 A). Cells undergoing late 
apoptosis were identified as double positive for Annexin V and PI (Fig. 6.18 B).  
 After 6 hours of culture, we found a significant decrease in the percentage 
of apoptotic apoE-/- MZ B compared to WT MZ B cells (Fig. 6.18 C), suggesting 
that apoE-/- MZ B cells were more resistant to death as compared to WT MZ B 
cells. In contrast, we found an increase in the percentage of apoptotic apoE-/- FOB 
cells compared to WT FO B cells (Fig. 6.18 D), suggesting that apoE-/- FOB cells 
were more vulnerable to death as compared to WT FOB cells. Taken together, a 
decrease in death of MZ B cells and an increase in death of FO B cells in cultured 
apoE-/- splenocytes correlate with the expansion of the MZ B cell compartment 
which was associated with a decrease in the FO B cell compartment in 
atherosclerotic apoE-/- mice. These results indicate that hypercholesterolemia was 
associated with decreased death of MZ B cells and increased death of FO B cells 
in apoE-/- mice. 
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Figure 6.18 Analysis of apoptosis in MZ B cells and FO B cells in 24 week old 
WT and apoE-/- mice. A) Experimental outline for the analysis of Annexin V and 
PI on MZ B cells and FO B cells in cultured splenocytes. B) Representative 
FACS plots of apoptotic MZ B cells and FO B cells from 24 week old WT and 
apoE-/- mice fed a HF diet. Apoptotic MZ B cells were identified as Annexin V+ 
PI+ B220+ CD21high CD23low while apoptotic FO B cells were identified as 
Annexin V+ PI+ B220+ CD23high CD21low. C) Percentage of apoptotic MZ B cells 
D) Percentage of apoptotic FO B cells. Results are pooled from 2 independent 
experiments with 3 to 4 mice per group in each experiment. Significant 
differences were designated as *p<0.05. Error bars represent SD. 
C 
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6.3.3 The cholesterol lowering drug Ezetimibe increases MZ B cells death in 
apoE-/- mice 
 Since hypercholesterolemia was associated with decreased death of MZ B 
cells in apoE-/- mice, we hypothesized whether reducing cholesterol could reverse 
the effect on MZ B cells death. To address this question, 12 week old apoE-/- mice 
were treated with the cholesterol lowering drug Ezetimibe for 3 months. 
Splenocytes were cultured for 6 hours in the absence of stimulation and apoptotic 
MZ B cells and FO B cells were detected by flow cytometric staining of Annexin 
V and PI (Fig. 6.19 A). Results reveal an increase in the percentage of Ezetimibe 
treated apoptotic apoE-/- MZ B cells compared to non treated apoptotic apoE-/- MZ 
B cells after 6 hours of culture (Fig. 6.19 B). Interestingly, the percentage of 
Ezetimibe treated apoptotic FO B cells decreased significantly compared to non 
treated apoE-/- apoptotic FO B cells (Fig. 6.19 C). These results suggest that 
lowering cholesterol in apoE-/- mice increases death of MZ B cells and decreases 










Figure 6.19 Flow cytometric analysis of apoptotic MZ B cells and FO B cells 
from Ezetimibe treated mice. A) Diagram depicting the ezetimibe drug 
treatment procedure and analysis of apoptosis in MZ B cells and FO B cells. 
Results are representative with an average of 3 to 4 mice per group. Significant 





	   122	  
6.3.4 Death of MZ B cells after exogenous α-GalCer treatment is regulated by 
iNKT cells 
 A recent study showed that iNKT cells were required in the regulation of 
MZ B cell death (Wen, Yang et al. 2011). In this study, the injection of α-GalCer 
into WT mice led to a 2 fold decrease in the percentage of MZ B cells, suggesting 
that iNKT cell activation induced MZ B cell death. Interestingly, iNKT cells in 
hyperlipidemic apoE-/- mice were found to be anergic and they fail to produce 
IFN-γ and IL-4 cytokines after exogenous α-GalCer stimulation (Braun, Mendez-
Fernandez et al. 2010). These findings led us to speculate that the loss of iNKT 
cell function in apoE-/- mice renders them resistant to iNKT cell induced MZ B 
cell death.  
 First, we wanted to confirm that the death of MZ B cells after α-GalCer 
injection was due to the effect of iNKT cells. To address this, we injected 1µg of 
α-GalCer into Jα18-/- mice which specifically lack iNKT cells (Wakao, Kawamoto 
et al. 2007). On day 1 or 3, the spleens were harvested and the percentages of MZ 
B cells and iNKT cells were quantified by flow cytometry. As α-GalCer activates 
iNKT cells in a CD1d dependent manner, fluorescently labelled CD1d tetramers 
loaded with α-GalCer were used to detect iNKT cells (Fig.6.20 A).   
 Consistent with prior studies (Parekh, Wilson et al. 2005), we found that 
rapidly (1 day) after α-GalCer administration into WT mice, iNKT cells became 
undetectable by tetramer staining due to TCR downregulation. NKT cells then 
expanded at 3 days. We could not detect any positive tetramer staining in Jα18-/- 
mice, confirming the deficiency of iNKT cells in these mice (Fig. 6.20 B). 
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 The administration of α-GalCer into WT mice led to a significant decrease 
in the MZ B cells percentage. In contrast, we did not observe any changes in the 
percentage of MZ B cells in Jα18-/- mice treated with α-GalCer at Day 3 (Fig. 6.20 
C). These results provide direct evidence that the death of MZ B cells was 
mediated by activated iNKT cells. 
 
6.3.5 Dysfunctional iNKT cells are associated with MZ B cells expansion in 
atherosclerotic apoE-/- mice 
 Having confirmed that the activation of iNKT cells was required for 
inducing MZ B cell death in WT mice, we went on to determine whether 
dysfunctional iNKT cells in apoE-/- mice could cause MZ B cell expansion. We 
activated iNKT cells by injecting 1µg of α-GalCer into 24 week old WT and 
apoE-/- mice fed a HF diet. To access the function of iNKT cells, mice were bled 4 
hours post activation and the serum was collected for measurement of IFN-γ and 
IL-4 by ELISA. The spleen was collected after 3 days and the percentage of MZ 
B cells was quantified by flow cytometry (Fig. 6.21 A). 
 Compared to WT mice, the serum IL4 and IFN-γ levels were greatly 
blunted in apoE-/- mice after iNKT cell activation (Fig. 6.21 B, C). This confirms 
previous reports showing that iNKT cells in hyperlipidemic mice exhibit 
decreased production of IL-4 and IFN-γ upon activation (Braun, Mendez-
Fernandez et al. 2010). We quantified the percentage of MZ B cells in the spleens 
at Day 3. Consistent with previous reports, we saw a 2 fold decrease in the 
percentage of MZ B cells in WT mice treated with α-GalCer (Fig. 6.21 D). 
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However, we did not observe any changes to the MZ B cell percentage in apoE-/- 
mice treated with α-GalCer (Fig. 6.21 D), suggesting that the expansion of MZ B 
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Figure 6.20 Death of MZ B cells after α-GalCer stimulation requires iNKT 
cells. A) Experimental outline of α-GalCer treatment in 6 week old WT and Jα18-
/- mice. B) FACS plots showing iNKT cells stained with fluorescently labeled 
CD1d tetramer after α-GalCer injection in WT and Jα18-/- mice C) Percentage of 
MZ B cells in WT and Jα18-/- mice after α-GalCer injection. Significant 
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Figure 6.21 Analysis of iNKT cell function and percentage of MZ B cells after 
α-GalCer injection. A) Experimental outline of α-GalCer treatment in 22-28 
week old WT and apoE-/- mice fed a HF diet. B) Serum IFN-γ C) Serum IL-4 D) 
Percentage of MZ B cells. Results are representative of 2 independent 
experiments (n=4). Significant differences were designated as *p<0.05. 
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6.3.6 Anergic iNKT cells are responsible for the expansion of MZ B cells in 
atherosclerotic apoE-/- mice 
 Since we found an association between anergic iNKT cells and the 
expansion of MZ B cells in apoE-/- mice, we decided to directly test whether 
anergic iNKT cells may lead to MZ B cell expansion by inducing iNKT cell 
anergy in WT mice. To address this hypothesis, a very high dose of α-GalCer 
(5µg) was preinjected into 20 week old WT mice fed a chow diet to induce iNKT 
cell anergy (Parekh, Wilson et al. 2005). The mice were restimulated with 1µg of 
α-GalCer 1 month later. To determine the activation status of iNKT cells, mice 
were bled 4 hours after restimulation and the serum was collected for 
quantification of cytokines (IFN-γ and IL-4) by ELISA. On Day 3 after 
restimulation, the mice were euthanized and the spleens were collected for 
quantification of the percentage of MZ B cells and iNKT cells by flow cytometry 
(Fig. 6.22 A). 
 We compared the iNKT cell responses to α-GalCer in naïve mice versus 
mice that had been injected 1 month earlier with a single dose of α-GalCer. On 
day 3, α-GalCer administration resulted in an expansion of iNKT cells in WT 
mice that were not preinjected with α-GalCer 1 month earlier (Fig. 6.22 D). In 
contrast, iNKT cells from mice that were injected 1 month earlier with α-GalCer 
failed to expand in response to α-GalCer restimulation (Fig. 6.22 D). We also 
tested the capacity of α-GalCer to induce IL-4 and IFN-γ in the serum of mice 
injected 1 month earlier with α-GalCer. The absence of iNKT cell proliferation in 
mice that were pretreated with α-GalCer was accompanied by a lack of cytokine 
production (IL-4 and IFN-γ) upon α-GalCer rechallenge (Fig. 6.22 B, C). Mice 
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that were not pretreated with α-GalCer showed a significant increase in the 
cytokine production (IL-4 and IFN-γ) upon α-GalCer stimulation (Fig. 6.22 B, C). 
These results indicate that the preinjection of α-GalCer into WT mice 1 month 
earlier induced iNKT cell anergy. We went on to determine whether induction of 
iNKT cell anergy affected the percentage of MZ B cells in the spleen. 
Interestingly, we found a 2 fold increase in the percentages of MZ B cells in WT 
mice that were pretreated with α-GalCer 1 month earlier compared to mice that 
were not preinjected (Fig. 6.22 E). These results provide evidence to suggest that 
the induction of iNKT cell anergy leads to an increase in the MZ B cell 



























Figure 6.22 Inducing iNKT cell anergy expands MZ B cells in WT mice. A) 
Diagram depicting induction of iNKT cell anergy in 20 week old WT mice B) 
Serum IL-4 C) Serum IFN-γ D) Percentage of iNKT cells E) Percentage of MZ B 
cells. Significant differences were designated as ***p<0.001. Results are pooled 
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6.3.7 Adoptive transfer of WT iNKT cells but not IFN-γ-/- iNKT cells into 
apoE-/- mice reverses the expansion of MZ B cells 
To provide direct evidence that iNKT cell anergy accounts for MZ B cell 
expansion in apoE-/- mice, we evaluated the effect of transferring functional WT 
iNKT cells into apoE-/- mice on the MZ B cell compartment in these mice. 5x105 
iNKT cells isolated from WT mice were adoptively transferred into 20 week old 
recipient apoE-/- mice one day before stimulation with α-GalCer. Compared to 
non-recipient apoE-/- mice, apoE-/- mice that received WT iNKT cells showed a 
significant increase in the production of IFN-γ but not IL-4 after α-GalCer 
stimulation (Fig. 6.23 A, B). In addition, the adoptive transfer of WT iNKT cells 
in apoE-/- mice significantly decreased the percentage of MZ B cells to WT levels 
(Fig. 6.23 C). These results suggest that the adoptive transfer of functional WT 
iNKT cells into apoE-/- mice significantly increased the production of IFN-γ upon 
stimulation and reversed the expansion of MZ B cells.  
Since IFN-γ production in response to α-GalCer stimulation was more 
affected than IL-4 response in apoE-/- mice, we hypothesized that activated iNKT 
cells may induce MZ B cell death via secretion of IFN-γ. To test this hypothesis, 
5x105 IFN-γ-/- iNKT cells were adoptively transferred into 24 week old recipient 
apoE-/- mice one day prior stimulation with α-GalCer. The adoptive transfer of 
IFN-γ-/- iNKT cells into apoE-/- mice did not restore IFN-γ production after α-
GalCer stimulation  (Fig. 6.24 B) and the percentage of MZ B cells remained 
unaffected (Fig. 6.24 C). Altogether, these results show that the death of MZ B 
cells induced by activated iNKT cells was in part mediated by IFN-γ and this 
regulatory process mediated by iNKT cells is altered in hyperlipidemic mice.  
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Figure 6.23 Adoptive transfer of WT iNKT cells reverses MZ B cell 
expansion. A) Serum IL-4 B) Serum IFN-γ C) Percentage of MZ B cells. 
Significant differences were designated as *p<0.05, **p<0.005. Results are 








Figure 6.24 Adoptive transfer of IFN-γ-/- iNKT cells does not affect MZ B cell 
expansion. A) Serum IL-4 B) Serum IFN-γ C) Percentage of MZ B cells. 
Significant differences were designated as *p<0.05, **p<0.005, ***P<0.001. 














	   135	  
Summary 
 Taken together, our results suggest that the expansion of MZ B cells was 
not associated with increased survival due to elevated BAFF and BAFFR levels. 
Consistent with prior studies, our results revealed that the activation of iNKT cells 
was important for causing death of MZ B cells. We also showed that the 
expansion of MZ B cells in apoE-/- mice was associated with iNKT cells 
dysfunction. By inducing iNKT cell anergy in WT mice, we were able to increase 
the MZ B cell percentage by 2 fold. In addition, the adoptive transfer of WT 
iNKT cells but not IFN-γ-/- iNKT cells into apoE-/- mice reversed MZ B cell 
expansion. Collectively, these results provide evidence to suggest that the absence 
of IFN-γ secretion due to iNKT cell anergy was responsible for the expansion of 
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Chapter 7 Discussion 
 
7.1 The role of B lymphocyte subsets in atherosclerotic apoE-/- mice 
In the first part of our study, we qualitatively and quantitatively 
characterized two B2 cell subpopulations in the spleen, FO B cells and MZ B 
cells. We showed that the percentage and number of MZ B cells increased by 2 
fold in 20 week old atherosclerotic apoE-/- mice fed a HF diet. A similar 
expansion was also seen in 60 week old apoE-/- mice fed a chow diet. The 
expansion of MZ B cells was associated with a decrease in the FO B cell 
compartment in apoE-/- mice. As each of these splenic B cell subpopulations 
possess unique properties and functions, they may contribute to atherosclerosis in 
different ways. Indeed, studies by multiple groups revealed that B lymphocyte 
subsets have different effects on atherosclerosis. This was illustrated in a study by 
Kyaw et al 2010, where the transfer of conventional B2 cells but not B1 cells into 
B cell-deficient atherogenic mice (apoE-/- µMT-/-) augmented atherosclerosis. This 
seem to suggest that the effect of B cells on atherosclerotic disease may be subset 
dependent, with FO B cells and MZ B cells being pro-atherogenic. Also, the 
proatherogenic potential of B2 cells may require the interaction of B cells and 
other lymphocyte populations. However, MZ B cells may be able to produce IgM 
antibodies which are atheroprotective. Since the majority of B cells in the B2 
population are FO B cells, it is possible that the protective effect of IgM 
producing MZ B cells may not be enough to counteract the proatherogenic effect 
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of FO B cells. Further studies are required to confirm the role of various B cell 
subsets in atherosclerotic disease progression.  
7.2 Functional significance of MZ B cells expansion in atherosclerosis 
Reports have shown a similar expansion of MZ B cells in mouse models 
of autoimmune diseases such as SLE and diabetes. It has been hypothesized that 
MZ B cells may play a role in the initiation and pathogenesis of these diseases.  
NZB/NZW F1 mice which develop SLE have been shown to be associated 
with an expanded population of MZ B cells that spontaneously secrete large 
amounts of anti-DNA IgM and IgG in vitro (Roark, Park et al. 1998, Zeng, Lee et 
al. 2000). In another model of drug-induced lupus, estrogen treatment of normally 
tolerant anti-DNA heavy chain transgenic BALB/c mice led to an enlargement of 
the MZ B cell pool that contributes to the pathogenic autoantibody responses by 
producing large amounts of anti-dsDNA IgM antibodies (Grimaldi, Michael et al. 
2001). Likewise, treatment of mice with the hydrocarbon oil pristine, which 
produces a lupus-like syndrome, expands MZ B cells (Yang, Singh et al. 2003). 
Non obese diabetic (NOD) mice model for type 1 diabetes develops an 
abnormally enlarged MZ B cell compartment which are highly efficient at 
capturing soluble islet-derived antigens and presenting them to diabetogenic T 
cells (Marino, Batten et al. 2008). Taken together, these studies show that the 
expansion of MZ B cells may play important roles in the pathogenesis of 
autoimmune diseases. However, the differences in autoimmune models and MZ B 
cell frequency appear to be dependent on the different pathways involved in the 
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respective models. Nevertheless, the analysis of these auto-reactive MZ B cells 
may provide insights into the functions of MZ B cells in atherosclerosis.  
MZ B cells are optimally positioned to detect pathogens in the 
bloodstream and are thus in a prime position to monitor changes in LDL/oxLDL 
levels, resulting in an immune response towards this atherogenic antigen. MZ B 
cells are known to be one of the major producers of natural IgM antibodies. In 
human and animal models of atherosclerosis, titers of antibodies against oxLDL 
correlate with atherosclerotic lesion formation and are often used as predictors for 
atherosclerosis development (Salonen, Yla-Herttuala et al. 1992, Maggi, Chiesa et 
al. 1994, Palinski, Tangirala et al. 1995, Palinski, Horkko et al. 1996). In our 
study, we have shown that MZ B cells are able to rapidly uptake dil-oxLDL. In 
addition, we found that the expansion of MZ B cells was associated with an 
increase in total IgM as well as lipid specific (LDL/oxLDL) IgM antibodies in 
cultured apoE-/- splenocytes compared to WT splenocytes. In addition, a robust 
extrafollicular response involving an increased production of total and oxLDL 
specific IgM antibodies was observed in the apoE-/- spleen (data generated by lab 
member). Given that MZ B cells respond to TI-2 antigens in vivo and an 
expansion was found in the spleen of apoE-/- mice, it is possible that MZ B cells 
may participate in the extrafollicular reaction, giving rise to the increase in total 
IgM responses. However, we were unable to detect LDL and oxLDL specific IgM 
antibodies in sorted MZ B cells. This could possibly be due to insufficient MZ B 
cell numbers being seeded or the lack of antigen stimulation and survival factors 
present in splenocytes that could aid in the survival and production of lipid 
	   139	  
specific antibodies by MZ B cells.  Moreover, it is also possible that MZ B cells 
require specific interactions with other cell types, for example iNKT cells and 
DCs, in order to mount an efficient antibody response to lipid antigens. 
Splenocytes may contain survival factors and a myriad of different cell 
populations that could aid in the LDL/oxLDL IgM antibody response. Thus, the in 
vitro environment which lacks these survival factors and cell interactions may not 
be conducive for sorted MZ B cells to produce detectable amounts of 
LDL/oxLDL specific antibodies. This could be one of the reasons why we 
succeeded in detecting lipid specific antibodies produced in cultured splenocytes 
but not in sorted MZ B cells. Further investigations will be required to determine 
whether MZ B cells may contribute to the oxLDL IgM antibody response in the 
spleen.  
In addition, we cannot rule out the possibility that other subpopulations of 
B cells such as B1a B cells which are the major producers of natural IgM 
antibodies may also contribute to the production of lipid specific IgM antibodies 
in the spleen.  
How does an increased titer of IgM and LDL/oxLDL IgM antibodies 
affect atherosclerosis development? In humans, oxLDL IgM antibodies were 
found to be inversely associated with the outcome of cardiovascular disease while 
a positive association was observed for oxLDL IgG antibodies (Tsimikas, Brilakis 
et al. 2007). A significant increase in plaque size was reported in atherosclerotic 
mice that lacked serum IgM (Lewis, Malik et al. 2009). Thus, at present, the 
widely held view is that the IgM response to oxLDL is atheroprotective while the 
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IgG response is pro-atherogenic (Shoenfeld, Wu et al. 2004, Lewis, Malik et al. 
2009). It is proposed that IgG antibodies bound to oxLDL may promote 
atherosclerosis through inducing macrophage activation via Fcγ-receptors (FcγR), 
resulting in the release of inflammatory cytokines and the formation of foam cells, 
which are the hallmarks of early atherosclerotic fatty streak lesions. In contrast, 
oxLDL IgM immune complexes are unable to bind to FcγRs on macrophages, 
preventing macrophage activation and the formation of foam cells (Huang, 
Fleming et al. 2000). In addition, oxLDL IgM antibodies can promote the 
clearance of oxLDL distant from the lesion prone site with the help of 
complement components. In support of this, C3-deficient ldlr-/- mice develop 
increased atherosclerosis (Buono, Come et al. 2002). However, the biological 
relevance for these mechanisms for protective antibodies remains controversial 
because a study conducted by Reardon showed that there were similar rates of 
clearance of native human LDL or oxLDL in immunocompetent apoE-/- mice and 
immunocompromised apoE-/- Rag2-/- mice despite the detection of in vivo 
circulating immune complexes (Reardon, Miller et al. 2004). It is also possible 
that the formation of circulating immune complexes without immediate clearance 
may provide a protective effect by retaining oxLDL within the vessel, preventing 
their interaction with cells of the vessel wall.  
OxLDL IgM antibodies may have an additional function to neutralize the 
proinflammatory properties of oxidized phospholipids present in apoptotic blebs 
or oxLDL, preventing endothelial cell activation, tissue factor expression and 
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induction of cell death which therefore protects against atherosclerosis (Chisolm 
and Steinberg 2000, Huber, Vales et al. 2002, Steinberg 2002). 
Thus, an enlargement of the MZ B cell population may be beneficial to 
atherosclerotic diseases as they are able to produce protective IgM antibodies.  
In the second part of this thesis, we explored the possible mechanisms 
underlying the expansion of the MZ B cell compartment in apoE-/- mice. The 
expansion could be due to factors involved in their development, survival/death or 
proliferation.  
7.3 Possible mechanisms underlying MZ B cell expansion in 
hypercholesterolemic apoE-/- mice 
7.3.1 Developmental factors do not account for MZ B cells expansion 
First, we hypothesized whether the enlargement of the MZ B cell pool 
could be attributed to alterations in the development of MZ B cells. MZ B cells 
and FO B cells need to pass through T1 and T2 stages of B cell development 
before developing into mature B cells. It was previously reported that the 
expansion of MZ B cells was accompanied by an increase in the T2 MZP cell 
population in the NOD mouse model of type 1 diabetes (Marino, Batten et al. 
2008). Thus, an increase in transitional B cell precursor populations could 
potentially explain the increase in size of the MZ B cell pool. However, we failed 
to find any differences in the percentage of both T1 and T2 transitional precursor 
cell populations, indicating that the expansion of MZ B cells was not due to an 
increase in the precursor cell populations. MZ B cells and FO B cells develop 
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from a common precursor cell, the T2 MZP cell. B cell development could be 
skewed towards the differentiation of MZ B cells instead of FO B cells such that 
more of the T2 MZP cells develop into MZ B cells, resulting in a decrease in the 
FO B cell compartment. We assessed a number of factors that could take part in 
the regulation of MZ B/FO B cell fate. Notch 2-DL1 signaling in which is 
negatively regulated by MINT, favors the commitment to a MZ B cell fate. 
However, we did not find any significant differences in the mRNA expression of 
Notch 2 and MINT in sorted transitional cell populations and MZ B cells 
collected from 24 weeks old WT and apoE-/- mice. In addition, we could not 
detect any increase in the Notch ligand DL1 in the spleens of diseased apoE-/- 
mice. These results suggest that the expansion of MZ B cells was not associated 
with an increase in Notch 2 signaling. We investigated further into helix loop 
helix proteins which were proposed to be a deciding factor for T2 MZPs to 
develop into either a MZ B cell or FO B cell. Abundant E2A promotes a FO B 
cell fate while expression of the ID2/ID3 proteins, which are antagonistic for E2A 
allows the T2 precursor cell to develop into MZ B cells. A decrease in E2A 
coupled with an increased expression of ID proteins would promote the 
development of MZ B cells over FO B cells, resulting in an enlarged MZ B cell 
compartment. However, we did not find any differences in the mRNA expression 
levels of E2A and ID proteins in sorted transitional B cells and MZ B cells 
isolated from 24 weeks old WT and apoE-/- mice. Lastly, because an expanded 
MZ B cell compartment was reported in mice deficient for Fli-1, we quantified 
the mRNA expression levels of Fli-1 and its downstream target genes mb-1 and 
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Igα (CD79a). Similarly, we did not observe any difference in the mRNA 
expression of Fli-1, mb-1 and Igα in sorted transitional B cells and MZ B cells 
collected from 24 weeks old WT and apoE-/- mice.  There is an absence of MZ B 
cells in BCL-2 transgenic mice while BCL-2 knockout mice have increased MZ B 
cell numbers (Brunner, Marinkovic et al. 2003). We also failed to detect any 
difference in the mRNA expression of BCL-2, whose expression is controlled by 
Fli-1. Taken together, these results indicate that the expansion of MZ B cells in 
atherosclerotic apoE-/- mice was not related to the developmental factors 
mentioned above. As this is not an exhaustive list of developmental factors, we 
cannot rule out the possibility that other unexplored factors involved in the B cell 
developmental pathway were involved.  
7.3.2 iNKT cells and control of MZ B cells 
CD1d on antigen presenting cells is required for presentation of glycolipid 
antigen to iNKT cells which could in turn provide help for MZ B cells to 
proliferate. As MZ B cells express high levels of CD1d, we speculate that an 
increase in CD1d lipid presentation to iNKT cells could result in more help for 
MZ B cells proliferation responses. However, we could not find an increase in the 
expression of CD1d on MZ B cells. We also tested out this hypothesis by 
administering a blocking antibody for CD1d. We showed that blocking CD1d did 
not affect the percentages of proliferating MZ B cells and FO B cells, suggesting 
that iNKT cells do not promote an increase in proliferation in apoE-/- mice and 
thus cannot account for their expansion. 
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As the expansion could also be due to an increase in the inherent ability of 
MZ B cells to proliferate, we checked the proliferative status of MZ B cells from 
WT and apoE-/- mice through MUH studies and Ki67 staining and showed that 
there was no increase in the intrinsic proliferation capacity of apoE-/- MZ B cells 
compared to WT MZ B cells. Taken together, this study confirmed that the 
expansion of MZ B cells in apoE-/- mice was not due to their increased 
proliferation. 
We also compared the activation status and intrinsic proliferative capacity 
of MZ B cells between 20 weeks old WT and apoE-/- mice. We showed that the 
activation status of MZ B cells was not increased in apoE-/- mice judging by 
similar expression levels of CD69 and co-stimulatory molecules CD40, CD80 and 
CD86 between WT and apoE-/- MZ B cells. Thus the expansion of MZ B cells 
could not be explained by an increase in their activation which results in greater 
proliferation. 
7.3.3 BAFF-BAFFR signaling does not promote increased survival of MZ B cells 
in apoE-/- mice 
Next, we wondered whether increased survival could account for the 
expansion of MZ B cells in apoE-/- mice. Elevated levels of BAFF have been 
implicated in autoimmune diseases exhibiting an expanded population of MZ B 
cells. BAFF transgenic mice have an abnormally large MZ B cell compartment. 
Macrophages and DCs are involved in the production of BAFF. An increase in the 
percentage of DCs in apoE-/- mice could potentially lead to an increase in BAFF 
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production. However, we did not find any significant difference in the mRNA and 
protein levels of BAFF in the serum and spleens of 24 weeks WT and apoE-/- 
mice. We further examined the expression of BAFFR on T2 MZP cells and MZ B 
cells. We did not detect any increase in the expression of BAFFR between 24 
weeks WT and apoE-/- mice in T2 MZP and MZ B cells. These results are also 
consistent with our findings on the lack of difference in Bcl-2 gene expression 
between 24 weeks WT and apoE-/- mice because BAFF prolongs B cell survival 
by regulating the expression of Bcl-2 (Batten, Groom et al. 2000). Therefore, the 
expanded MZ B cell compartment observed in atherosclerotic apoE-/- mice was 
not related to their increased survival mediated through BAFF and BAFFR 
signaling.  
7.3.4 iNKT cell anergy and MZ B cell death 
In our study, we showed that the expansion of MZ B cells in 
hypercholesterolemic apoE-/- mice was associated with a decrease in the 
proportion of MZ B cells undergoing apoptosis. Conversely, reversing 
hypercholesterolemia resulted in an increase in the percentage of apoptotic MZ B 
cells in apoE-/- mice. An important role for iNKT cells in the regulation of MZ B 
cells death has recently been highlighted in a study by Wen et al, where the 
exogenous activation of iNKT cells through the administration of α-GalCer 
induced death of MZ B cells in WT mice (Wen, Yang et al. 2011). This regulation 
was mediated in part via CD1d on B cells in a contact dependent manner. 
However, our results showed that blocking CD1d in apoE-/- mice did not reverse 
MZ B cell expansion. The discrepancy between our study and Wen’s could 
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possibly be due to the different strategies used. Wen et al 2011 demonstrated that 
the effect of iNKT cells on MZ B cell death was CD1d dependent through the use 
of CD1d deficient mice. We started treating hyperlipidemic apoE-/- mice at 15-20 
weeks of age where it may be too late to have any effect on the expansion of MZ 
B cells. 
iNKT cells are a unique subset of T cells that recognize glycolipid 
antigens and they play a role in the regulation of inflammation and immunity. 
Multiple studies have shown that the activation of iNKT cells is pro-atherogenic 
and that the hyperlipidemic conditions in the apoE-/- mice results in anergic iNKT 
cells with decreased functions. As the expansion of MZ B cells only occurs during 
the advanced stage of the disease where hypercholesterolemia is already well 
established and reversing hypercholesterolemia decreased MZ B cells back to WT 
levels, these observations seemed to suggest that chronic lipid exposure and 
activation of iNKT cells results in their development of an anergic phenotype 
which could possibly explain the decrease in percentage of apoptotic MZ B cells 
that causes their expansion. In our study, we showed that the expansion of MZ B 
cells in hypercholesterolemic apoE-/- mice was associated with anergic iNKT cells. 
Upon α-GalCer administration, WT iNKT cells rapidly secrete large amounts of 
cytokines IL-4 and IFN-γ, which led to a 2 fold decrease in MZ B cells. In stark 
contrast, apoE-/- iNKT cells showed a blunted cytokine response after α-GalCer 
administration which was associated with a lack of MZ B cell death. It is 
speculated that the anergic iNKT cell phenotype we observed in apoE-/- mice was 
due to their chronic activation by elevated levels of lipids. Thus, it could be 
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possible that the presence of an endogenous lipid ligand in the spleen may be 
responsible for the chronic activation and subsequent defect in iNKT cell function 
in apoE-/- mice. In addition, we also provided direct evidence to illustrate that 
anergic iNKT cells were responsible for the expansion of MZ B cells as the 
administration of a high dose of α-GalCer into WT mice led to a 2 fold increase in 
the MZ B cell percentage compared to untreated WT mice. The findings in this 
study is consistent with prior reports showing that splenic iNKT cells in apoE-/- 
mice develop spontaneous anergy and have an impaired ability to respond to 
exogenous stimulation by the glycolipid α-GalCer. This defective cytokine 
production affected IFN-γ responses more than IL-4 (Braun, Mendez-Fernandez 
et al. 2010). It has been reported that iNKT cells are not spontaneously activated 
in non-hypercholesterolemic apoE-/- mice at 5 weeks of age. We have also shown 
that young apoE-/- mice do not develop an expanded MZ B cell compartment, 
supporting the hypothesis that anergic iNKT cells are required for MZ B cells 
expansion. In addition, the adoptive transfer of functional WT iNKT cells into 
apoE-/- mice reversed MZ B cell expansion, suggesting that reintroducing 
functional iNKT cells into apoE-/- mice was sufficient to restrain the accumulation 
of splenic MZ B cells. 
How may iNKT cell anergy cause an expansion of MZ B cells? Since IL-4 
and IFN-γ production was highly suppressed in hyperlipidemic apoE-/- mice upon 
iNKT cell activation, we speculated that iNKT cells may promote death of MZ B 
cells in a cytokine dependent manner. IFN-γ is a cytokine that controls the Th1 
response against viral and intracellular bacterial infections. It negatively regulates 
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B cell differentiation and proliferation by mediating apoptosis (Grawunder, 
Melchers et al. 1993, Garvy and Riley 1994). Studies have shown that IFN-γ 
induces apoptosis in normal pre-B cell lines (Yoshikawa, Nakajima et al. 2001). 
In our study, we show that IFN-γ production by iNKT cells was required to 
induce the death of MZ B cells because the transfer of IFN-γ-/- iNKT cells into 
apoE-/- mice failed to reverse the expansion of MZ B cells. In addition, the 
transfer of functional WT iNKT cells into apoE-/- which reversed MZ B cell 
expansion was associated with a marked increase in IFN-γ but not IL-4 cytokine 
production upon α-GalCer stimulation. Since α-GalCer stimulation in IFN-γ-/- 
mice failed to decrease the percentage of MZ B cells compared to WT mice, we 
proved that IFN-γ is required for inducing the death of MZ B cells in vivo. In fact, 
the IFN-γ cytokine response towards α-GalCer was highly suppressed compared 
to the IL-4 cytokine response in apoE-/- mice. Thus, the absence of MZ B cell 
death upon α-GalCer stimulation in apoE-/- mice is likely be attributed to the 
decrease in IFN-γ production by iNKT cells. IL-4 has been shown to protect B 
lymphocytes from death by upregulating the transcription of Bcl-xl in a Stat6-
dependent manner (Wurster, Rodgers et al. 2002). Although the production of IL-
4 after iNKT cell activation in apoE-/- mice was decreased, low levels of IL-4 
were still detected and together with the absence of IFN-γ production may aid in 
the increased accumulation of MZ B cells. 
It is also possible that anergic iNKT cells could cause an expansion of MZ 
B cells through inhibiting mTOR signaling. A recent study by Wu et al 2014, 
revealed that iNKT cells deficient for Tuberous Sclerosis 1 (TSC1) are resistant to 
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anergy, highlighting a critical role for TSC1 in the induction of iNKT cell anergy. 
Anergic iNKT cells express elevated levels of TSC1, which is inhibitory to the 
mammalian target of rapamycin (mTOR) (Wu, Shin et al. 2014). Mice which had 
their B cells conditionally inactivated of TSC1 have hyperactive mTOR and 
exhibit a significant reduction in the percentage of splenic MZ B cells 
(Benhamron and Tirosh 2011). Interestingly, the administration of rapamycin, 
which inhibits mTOR caused a 2-fold increase in the percentage of MZ B cells in 
TSC1 deficient mice (Benhamron and Tirosh 2011). Thus, it is possible that 
elevated expression of TSC1 by anergic iNKT cells in apoE-/- mice inhibits 
mTOR signaling, resulting in the expansion of MZ B cells. 
How may an increase in TSC1 lead to iNKT cell anergy? Recent studies 
have demonstrated an increase in the expression of inhibitory markers 
Programmed Death-1 (PD-1) and PD-1 ligand (PD-L1) on iNKT cells made 
anergic by α-GalCer stimulation (Chang, Kim et al. 2008, Parekh, Lalani et al. 
2009). Studies have suggested that TSC1 could be a positive regulator for PD-1 
upregulation and TSC1 may promote iNKT cell anergy through upregulation of 
PD-1 (Wu, Shin et al. 2014). It was also reported that blocking PD-1 before 
activation by α-GalCer could prevent the development of iNKT cell anergy 
(Parekh, Lalani et al. 2009). However, blockade of PD-1 in young apoE-/- mice 
did not prevent the induction of iNKT cell anergy at a later age, suggesting that 
upregulating PD-1 is not the primary mechanism contributing to the development 
of anergic iNKT cells in hypercholesterolemic apoE-/- mice (Braun, Mendez-
Fernandez et al. 2010). 
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Another possible mechanism involves the phosphorylation of nuclear 
factor of activated T cells (NFAT) by mTOR, preventing its nuclear translocation 
required for inducing the production of anergy-promoting molecules (Yang, Yu et 
al. 2008). Thus, it is possible that an increase in TSC1 expression resulting in 
decreased mTOR activation prevents the phosphorylation of NFAT, allowing for 
its nuclear translocation that induces the subsequent production of anergy-
promoting molecules required for iNKT cell anergy.  
 
7.4 Hypothethical Model: Spontaneous iNKT cell anergy in apoE-/- mice 
inhibits MZ B cell death 
We propose a mechanism whereby the hyperlipidemic environment in 
apoE-/- mice allows for the uptake of an unknown lipid by MZ B cells, resulting in 
the specific activation of iNKT cells. During early stages of the disease where 
cholesterol levels have not reached elevated levels, iNKT cells are functional. 
They secrete cytokines (IFNγ and IL-4), do not express increased TSC1 levels 
and have normal mTOR signaling. Thus, MZ B cell expansion is inhibited. 
As the disease progresses, the hyperlipidemic environment in apoE-/- mice 
results in the repeated chronic activation of iNKT cells which renders them 
anergic. Anergic iNKT cells exhibit decreased functionality as seen by the blunted 
cytokine (IL-4 and IFN-γ) response upon activation. The upregulation of TSC1 in 
anergic iNKT cells inhibits mTOR signaling. The decrease in cytokine production 
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and inhibition of mTOR signaling may together or independently contribute to the 
expansion of MZ B cells.  
The expanded MZ B cell compartment may play a role in the production 
of protective IgM antibodies (Figure 7). 
 
 
Figure 7. Hypothetical model illustrating how iNKT cell anergy could result 
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7.5 Clinical significance 
CD1d positive cells have been detected in neovascularized atherosclerotic 
lesions isolated from patients who had previous cardiovascular events and not in 
the plaque of asymptomatic patients (Kyriakakis, Cavallari et al. 2010), 
suggesting a role for iNKT cells in the pathogenesis of human atherosclerosis. A 
large number of studies have shown that iNKT cells contribute to atherosclerosis 
progression and CD4+ iNKT cells were suggested to be the pro-atherogenic subset 
due to their increased ability to secrete pro-inflammatory cytokines IFN-γ, TNF-α 
and IL-2 upon in vitro α-GalCer stimulation (To, Agrotis et al. 2009). Therefore, a 
defect in iNKT cells in apoE-/- mice during advanced stages of the disease could 
possibly be protective. This protective effect could also be mediated indirectly 
through regulating the size of the MZ B cell population, which we speculate to be 
atheroprotective. Thus, understanding how these cells could potentially impact 
atherosclerotic disease progression may open up new methods for atherosclerotic 
disease treatment. Not only is it important to understand the functional properties 
of iNKT cells in chronic conditions of dyslipidemia such as atherosclerosis, but 
also in diseases for which therapeutic approaches involving manipulation of iNKT 
cells are being considered. Modulation of iNKT cell responses could also have 
potential clinical applications as a treatment for cancer, diabetes and HIV in 
humans. 
Current management of atherosclerosis includes cholesterol lowering 
drugs (statins), antihypertensive drugs and anti-platelet agents. Chronic 
inflammation is also a risk factor and a reduction in inflammation is essential for 
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minimizing the incidence of adverse cardiovascular events. Targeting 
proatherogenic B cells on top of cholesterol lowering may attenuate both 
inflammation and atherosclerosis. We speculate that MZ B cells could potentially 
have anti-atherogenic properties due to their ability to produce atheroprotective 
IgM antibodies. Understanding how these B cells may be activated to produce 
antibodies may provide novel pharmacological approaches to promote 
atheroprotection. In addition, knowing how the survival/death of B cells is 
regulated could aid in modulating the expansion of protective B cell subsets that 
could complement B cell targeted therapies in atherosclerosis management. 
7.6 Limitations of study 
This study does not directly address whether MZ B cells are pro or anti-
atherogenic. In addition, we were unable to detect the source of protective lipid 
specific (LDL/oxLDL) antibodies. We also did not directly address the cell type 
involved in antigen presentation to iNKT cells. MZ B cells highly express CD1d 
and possesses antigen presentation capabilities. As DCs also express CD1d, they 
may also potentially present glycolipid antigens to modulate iNKT cell responses.  
Whether DCs are involved in iNKT cell mediated MZ B cell death is still 
unknown. Whether anergic iNKT cells in diseased apoE-/- mice have inhibited 
mTOR activation/signaling is still uncertain. 
7.7 Future Directions 
Future studies will be designed to further elucidate the mechanisms by 
which iNKT cells mediate MZ B cell death. This will be addressed through the 
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reversal of iNKT cell anergy, which can be done using different approaches. We 
have shown in this study that the induction of disease regression by Ezetimibe 
treatment of diseased apoE-/- mice decreased MZ B cell expansion, which was 
associated with an increase in the apoptotic MZ B cell percentage. To test whether 
iNKT cells were able to regain their function at the end of the drug treatment 
regime, we will activate iNKT cells in Ezetimibe treated apoE-/- mice and 
determine if they are able to produce cytokines (IL-4 and IFN-γ). 
We have also shown that the development of spontaneous iNKT cell 
anergy in apoE-/- mice was associated with decreased apoptotic MZ B cell death. 
In addition, we successfully induced the expansion of MZ B cells by rendering 
iNKT cells anergic in WT mice. These unresponsive iNKT cells continue to 
produce low levels of IL-4 but the IFN-γ response was severely blunted.  Previous 
studies have shown that administration of exogenous cytokine IL-2 can overcome 
conventional T cell exhaustion and break iNKT cell anergy (Parekh, Wilson et al. 
2005). Future studies involving the co-administration of IL-2 and α-GalCer into 
diseased apoE-/- would determine whether the reversal of iNKT cell anergy can 
induce MZ B cell death, which prevents their expansion.   
In order to determine whether IL-4 and IFN-γ are directly involved in 
regulating MZ B cell death in apoE-/- mice, neutralizing antibodies against IL-4 
and IFN-γ can be administered into WT or young apoE-/- mice after α-GalCer 
administration. 
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It will also be of interest to investigate whether decreased mTOR signaling 
could promote MZ B cell expansion in apoE-/- mice. As a first approach, we could 
determine the activity of mTOR in total splenocyte lysates by checking for 
phosphorylation of downstream mTOR targets such as S6 and EBP1. If mTOR 
activity is decreased or inhibited in the splenocyte lysates of apoE-/- mice, 
rapamycin treatment could be performed on young apoE-/- to inhibit mTOR. 
To directly test whether it is the lipids present in apoE-/- mice that may be 
required for inducing iNKT cell anergy, WT iNKT cells or iNKT cells isolated 
from non-lipidemic environment could either be cultured with apoE-/- serum or 
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7.8 Conclusion 
In conclusion, hypercholesterolemia is associated with the expansion of 
MZ B cells in apoE-/- mice. The enlargement of MZ B cell numbers observed was 
associated with the chronic activation of iNKT cells, which causes them to 
develop an anergic phenotype characterized by decreased cytokine IL-4 and IFN- 
γ secretion. We speculate that the expansion of MZ B cells could be caused by a 
lack of IFN-γ cytokine production by anergic iNKT cells and/or the inhibition of 
mTOR induced by upregulation of TSC1 expression. Due to the ability of apoE-/- 
MZ B cells to produce more total IgM antibodies, an expansion in this B cell 
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Appendix 1. Buffers and Media 
PBS (1x working concentration) 
8g NaCl, 0.2g KCL, 1.44g Na2HPO4, 0.24g KH2PO4 in 1litre of H2O, pH7.4 
MACS buffer 
0.5% BSA, 2mM EDTA in PBS, pH7.4 
10X TBS 
500mM Tris-HCL (78.82g), 1500mM NaCl (87.66g) in 1 litre of H2O, pH7.4 
ELISA Wash buffers (PBS-tween/ TBS-tween) 
0.05% Tween 20 in PBS/TBS 
0.9% Ammonium Chloride 
9g of Ammonium Chloride powder in 1 litre of H2O 
Complete RPMI 
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Appendix 2. List of antibodies used in flow cytometry 
Antibody Company Clone 
Rat anti-mouse B220-PerCP Cy5.5 BD Pharmingen RA3-6B2 
Rat anti-mouse IgM-FITC eBioscience H/41 
Strepavidin APC Invitrogen  
Anti-mouse Brdu BD Pharmingen  
CD1d tetramer APC NIH Tetramer 
Facility 
 
Rat anti-mouse CD21/CD35-PE eBioscience eBio8D9  
Armenian Hamster anti-mouse TCRβ PerCP 
Cy5.5 
eBioscience H57-597 
Rat anti-mouse CD8 PE eBioscience 53-6.7 
Rat anti-mouse CD4 eF450 eBioscience RM4-5 
Armenian Hamster anti-mouse TCRβ APC eBioscience H75-597 
Syrian Hamster anti-mouse CD3e PB BD Pharmingen 500A2 
Rat anti-mouse CD23 FITC eBioscience B3B4 
Rat anti-mouse CD23 PE eBioscience B3B4 
Rat anti-mouse B220 Biotin eBioscience RA3-6B2 
Rat anti-mouse B220 PB Caltag 
Laboratories 
RA3-6B2 
Rat anti-mouse IgM FITC Southern 
Biotech 
1B4B1 
Rat anti-mouse B220 FITC eBioscience RA3-6B2 
Rat anti-mouse CD1d PE eBioscience 1B1 
Rat anti-mouse IgM APC BD Pharmingen II/41 
Rat anti-mouse CD21/CD35 PerCP Cy5.5 Biolegend 7E9 
Rat anti-mouse B220 APC eBioscience RA3-6B2 
Rat anti-mouse CD11b PerCP Cy5.5 BD Pharmingen M1/70 
Armenian Hamster anti-mouse CD11c APC eBioscience N418 
Rat anti-mouse MHC Class II FITC eBioscience M5/114.15.2 
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Rat anti-mouse Moma-1 FITC AbD Serotec Moma-1 




Rat anti-mouse F4/80 Biotin AbD Serotec CI:A3-1 
Armenian Hamster anti-mouse CD69 PerCP 
Cy5.5 
BD Biosciences H1.2F3 
Rat anti-mouse CD86 (B7-2) APC eBioscience GL1 
Armenian Hamster anti-mouse CD80 (B7-1) 
APC 
eBioscience 16-10A1 
Rat anti-mouse CD40 APC eBioscience 1C10 
Mouse anti-mouse NK1.1 PE eBioscience PK136 
Purified Rat IgG2a Isotype control eBioscience  
Rat IgG2a Negative Control FITC AbD Serotec  
Rat IgG2a isotype control APC eBioscience  
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Appendix 3. List of antibodies used in immunofluorescence 
Antibody Company Clone 
Rat anti-mouse CD1d AbD Serotec 1B1 
Rat anti-mouse Moma-1 FITC AbD Serotec Moma-1 
Rat anti-mouse SIGNR1/ERTR9 Biotin Acris Antibodies 
GmbH 
ER-TR9 
Purified Rat IgG2a Isotype Control eBioscience  
Rat IgG2a Negative Control FITC AbD Serotec  
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Appendix 4: List of primers used in RT-PCR 
Target Gene Primer Sequence 
BAFF Forward 5’ ACACGCCGACTATACGAAAAGGAAC 3’ 
BAFF Reverse 5’ ACATCGGAACAGGGTCACCAGGCTCAG 3’ 
BCL-2 Forward 5’ GAGTTCGGTGGGGTCATGTG 3’ 
BCL-2 Reverse 5’ ATAGTTCCACAAAGGCATCCCAG 3’ 
DL-1 Forward 5’ GGGACAGAGGGGAGAAGATG 3’ 
DL-1 Reverse 5’ CACACCCTGGCAGACAGAT 3’ 
E2A- Forward 5’ CGGAGAGCTGCAGATGGTGGC 3’ 
E2A-Reverse 5’ AGGCTGCCATCTGCCACGTAGA 3’ 
Fli-1 Forward 5’ AATGGATCCAGGGAGTCTCCGGT 3’ 
Fli-1 Reverse 5’ TCGAACGTGCTCCTGTGTCCAC 3’ 
ID2- Forward 5’ ATCGCCCTGGACTCGCATCC 3’ 
ID2-Reverse 5’ GGGAATTCAGATGCCTGCAAGGACA 3’ 
ID3- Forward 5’ CTACTCGCGCCTGCGGGAAC 3’ 
ID3- Reverse 5’ AGCTCAGCTGTCTGGATCGGG 3’ 
CD79a- Forward 5’ TACTTACCTCCGCGTGCGCAATCCA 3’ 
CD79a- Reverse 5’ AGTCATCTGGCATGTCCACCCCA 3’ 
MINT- Forward 5’ GTCCAAGCATGAAGACTGGAG 3’ 
MINT- Reverse 5’ GGACCCTCTTCGTTCCTCTC 3’ 
Notch 2- Forward 5’ TGCCTGTTTGACAACTTTGAGT 3’ 
Notch 2- Reverse 5’ GTGGTCTGCACAGTATTGTCAT 3’ 
 
